Acquisition and application of a group of novel liver-targeting adeno-associated viruses

Through in vivo screening and targeted evolution methods, a new AAV capsid with enhanced targeting and immune evasion ability was obtained, solving the problem of limited targeting of existing AAV viral vectors and being affected by neutralizing antibodies, achieving more efficient genes Treatment effect.

CN116121275BActive Publication Date: 2024-11-29BEIJING SOLOBIO GENETECHNOLOGY CO LTD
View PDF 29 Cites 0 Cited by

Patent Information

Application Number
CN202211017942.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-07-29
Publication Date
2024-11-29
Estimated Expiration
2040-07-29

Smart Images

  • Figure CN116121275B_ABST
    Figure CN116121275B_ABST
Patent Text Reader

Abstract

The present invention provides a group of adeno-associated viruses with interesting properties obtained by directed evolution and in vivo screening methods, such as targeting properties and / or neutralization properties. The present invention also provides adeno-associated virus capsid proteins and virus particles comprising the adeno-associated virus capsid proteins, which have good or excellent targeting and / or neutralization properties.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention patent application with the application date of July 29, 2020, application number 202010742484.2, and invention name “Obtaining and applying a group of novel liver-targeted adeno-associated viruses”. Background Art

[0003] To date, adeno-associated virus (AAV) subtypes named by serotype are divided into AAV1-AAV12 (Gao Guangping et al., 2004, J Virolm 78:6381-6388; Mori S et al., 2004, Virology 330:375-383; Schmidt M et al., 2008, J Virol 82:1399-1406). They mainly use humans and primates as hosts. Among them, AAV1-6 is isolated from human tissues and has clear antibody reactivity, so it is more classic and recognized. AAV7 and AAV8 were rescued from macaque heart tissue by Gao Guangping et al. through genetic engineering. They are suspected to be AAV subtypes that have become extinct in evolution. This strategy provides new ideas and examples for the discovery of new AAV subtypes and the design and transformation of recombinant viruses (Gao Guangping et al., 2002, Proc Natl Acad Sci USA 99: 11854-11859), while AAV9-12 were prepared from human and macaque tissues using similar technical routes. Although viruses of different AAV serotypes have a regular icosahedral structure, the diversity of their capsid proteins in sequence and spatial conformation makes their cell surface binding receptors and cell infection tropism significantly different (Timpe J et al., 2005, Curr Gene Ther 5: 273-284). In terms of infection tropism, AAV2 has a wider infection spectrum, especially for nerve cells; AAV1 and AAV7 have higher transduction efficiency in skeletal muscle; AAV3 can easily transduce megakaryocytes; AAV5 and AAV6 have significant advantages in infecting respiratory epithelial cells; and AAV8 is more efficient in transducing hepatocytes than other subtypes.

[0004] The AAV virus itself is replication-deficient and can only be latent in host cells in the absence of a helper virus. The production of AAV viral vectors requires a helper plasmid to provide adenovirus (Ad) with key genes involved in AAV replication. These Ad genes include: early gene E1A is responsible for AAV transcriptional activity, early genes E1B and E4 are involved in the maturation of AAVmRNA, and early genes E2A and VA enhance AAV RNA translation (Berns et al., 1984, Adeno-associated virus 563–592).

[0005] As a gene therapy vector, recombinant adeno-associated virus (rAAV) has many advantages, such as high infection efficiency, wide infection range, long-term expression and high safety (David AF et al., 2007, BMC Bio 7:75), and has been widely used in clinical trials. Currently, there are more than 100 gene therapy projects using AAV as a vector entering clinical research, and the range of diseases treated has expanded to tumors, retinal diseases, arthritis, AIDS, heart failure, muscular dystrophy, nervous system diseases and a series of other genetic defect diseases.

[0006] Most of the ongoing clinical studies on gene therapy for eye diseases based on rAAV vectors are aimed at congenital amaurosis (LCA, Leber's congenital amaurosis) caused by mutations in the retinal pigment epithelium-specific 65kDa protein encoding gene (RPE65). The Luxturna drug developed by Spark was approved by the FDA for marketing in December 2017. This drug is rAAV2 carrying the hRPE65v2 gene to treat LCA and hereditary retinal dysplasia. The test results of the subjects after injection showed the effectiveness of the drug, and no obvious side effects were found, especially vector-related side effects (Russell S et al., 2017, Lancet 390: 849-860). Other gene therapy eye diseases that have entered clinical trials include choroideremia, and most studies are in clinical phases I and II. Among them, the University of Alberta used rAAV2 to carry the Rab guard protein 1 encoding gene (REP1) treatment project, and the results of the Phase I study published in 2018 showed the safety and effectiveness of the drug.

[0007] There are more than 20 clinical studies on hemophilia gene therapy based on rAAV vectors, among which hemophilia B has been studied the most. AAV gene drugs with long-term expression ability are ideal for the treatment of hemophilia B. UniQure is conducting a phase I / II clinical study using AAV5 to carry the human coagulation factor IX encoding gene (hFIX) to treat hemophilia B. Follow-up data one year after administration showed the safety of the drug. Patients developed a humoral immune response one week after administration, but it did not affect the expression level of coagulation factor IX, and T cell activation could not be detected using the current T cell detection "gold standard" system. Transaminases were elevated but did not affect FIX activity, and no hepatotoxic reactions were found (Miesbach W et al., 2018, Blood 131: 1022-1031). There are currently some gene therapy projects using AAV8 vectors to treat hemophilia. These are clinical studies targeting the liver (Nathwani AC et al., 2006, Blood. 107: 2653-2661). AAV8 is also currently recognized as the best AAV serotype for liver targeting.

[0008] Spinal muscular atrophy (SMA) refers to a class of diseases that cause muscle weakness and atrophy due to degeneration of the anterior horn cells of the spinal cord. AveXis' AVXS-101 is currently on the market. It uses the advantages of AAV9 in nervous system infection and carries the gene encoding the survival motor neuron protein (SMN1) to treat SMA, achieving good results. In clinical trials, all patients did not show clinical symptoms related to vector side effects (Mendell JR et al., 2017, N Engl J Med 377:1713-1722).

[0009] Other rare disease gene therapy projects using AAV as a vector, for example, use AAV1 to carry the acid α-glucosidase encoding gene (GAA) to treat Pompe disease (Smith BK et al., 2013, Hum Gene Ther 24:630-640), and use the modified AAV2.5 to carry the minidystrophin encoding gene to treat Duchenne muscular dystrophy (DMD) (Bowles DE et al., 2012, Mol Ther 20:443-455). The results of these clinical studies have shown the effectiveness and safety of the drugs.

[0010] The targeting of natural AAV is limited, especially when using AAV vectors for systemic administration. Depending on the serotype selected, the proportion of target cell tissues that can be effectively infected varies greatly, and the utilization rate of AAV is not maximized; in addition, other non-target tissue cells have the potential risk of being infected. In addition, because humans and other primates are naturally infected with AAV and produce neutralizing antibodies against natural AAV, this will greatly reduce the half-life of AAV and affect its drug activity.

[0011] Currently, there are more and more studies on the modification of AAV capsid protein. The purpose of the modification is: on the one hand, it can enhance the targeting of the viral vector, and on the other hand, it can reduce the immunogenic response of the viral vector.

[0012] For vector serotypes with relatively clear research on the mechanism of viral cell receptors, small-scale or site-specific modifications can be directly targeted at the amino acids in the cell receptor-related regions. The receptors of AAV2 on cells are currently relatively well studied. Heparan sulfate proteoglycan (HSPG) is the main cell receptor for AAV2 and AAV3. Changes in the amino acid sites R484, R487, K532, R585, and R588 on the AAV type 2 capsid protein will affect its binding to HSPG (Opie, SR et al., 2003, J Virol 77:6995–7006; Summerford, C et al., 1999, Nat Med 5:78–82).

[0013] The modified new AAV vector has been used in gene therapy clinical research, such as AAV2.5 carrying minidystrophin gene therapy for DMD (Bowles DE et al., 2012, Mol Ther 20: 443-455), whose Phase I clinical study has been completed, and a large number of studies have been conducted on the safety of the new AAV. The AAV2.5 capsid protein used in this project is a chimera, and the five amino acids related to skeletal muscle targeting in the AAV1 capsid protein are transplanted to the capsid protein of AAV2. This chimera not only enhances the targeting of skeletal muscle, but also has a significantly lower humoral immune response than AAV2. These clinical trials have proven the safety of the modified viral vector.

[0014] In addition, when the cell receptor mechanism of the virus is unclear, we can also use DNA shuffling or error-prone PCR methods to obtain the capsid protein of a new AAV virus vector with optimized function. For example, Grimm et al. used the shuffling library constructed by AAV to obtain a chimera AAV-DJ composed of AAV2, 8, and 9 under strict screening by intravenous immunoglobulin injection. This vector has a higher transduction efficiency for various cell lines such as fibroblasts and lungs (Grimm D et al., 2008, J Virol 82: 5887-5911). Jang et al. used the DNA shuffling library to screen a variant that can efficiently infect neural stem cells (Jang JH, 2011, Mol Ther 19: 667-675).

[0015] Currently, gene therapy drugs have become a hot topic of research at home and abroad. In order to make gene therapy drugs work better and longer, finding a new AAV vector with optimized functions to better meet the needs of gene therapy vectors is an urgent problem to be solved. Summary of the invention

[0016] Based on the need to find new AAV vectors, the present invention provides a group of viruses containing AAV capsids with interesting characteristics obtained by in vivo screening to achieve directed evolution of viruses, such as targeting characteristics and / or neutralizing characteristics (e.g., the ability to escape neutralizing antibodies). The present invention also provides AAV capsids and virus particles containing AAV capsids.

[0017] In one aspect, the present invention provides a nucleic acid encoding an AAV capsid protein, wherein the nucleic acid comprises an AAV capsid protein coding sequence selected from the following group:

[0018] (a) Figure 3A The nucleotide sequence of (L1) (SEQ ID NO: 1);

[0019] (b) Figure 3C The nucleotide sequence of (L4) (SEQ ID NO: 3);

[0020] (c) Figure 3E The nucleotide sequence of (L10) (SEQ ID NO:5);

[0021] (d) Figure 3G The nucleotide sequence of (L52) (SEQ ID NO:7);

[0022] (e) Fig. 3I The nucleotide sequence of (L58) (SEQ ID NO:9);

[0023] (f) Figure 3K The nucleotide sequence of (L84) (SEQ ID NO: 11);

[0024] (g) Figure 3M The nucleotide sequence of (L37) (SEQ ID NO: 13);

[0025] (h) Fig.3O The nucleotide sequence of (L107) (SEQ ID NO: 15);

[0026] (i) Figure 3Q The nucleotide sequence of (L57) (SEQ ID NO: 17); or

[0027] (j) A nucleotide sequence encoding an AAV capsid protein encoded by any one of the nucleotide sequences (a)-(i) but different from the nucleotide sequences (a)-(i) due to the degeneracy of the genetic code.

[0028] On the other hand, the present invention provides an AAV capsid protein encoded by the nucleic acid of the present invention, wherein the amino acid sequence of the AAV capsid protein is selected from any one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, or SEQ ID NO:18.

[0029] The present invention further provides a recombinant virus particle comprising a viral genome and an AAV capsid protein of the present invention, wherein the viral genome is encapsidated in the AAV capsid protein. The present invention further provides a recombinant adeno-associated virus particle comprising an AAV viral genome and an AAV capsid protein of the present invention, wherein the viral genome is encapsidated in the AAV capsid protein. In a specific embodiment, the viral genome is a recombinant vector genome comprising a heterologous nucleic acid.

[0030] The present invention provides a cell comprising the nucleic acid, AAV capsid protein, recombinant virus particles and / or recombinant adeno-associated virus particles of the present invention.

[0031] The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the nucleic acid, AAV capsid protein, recombinant virus particles, recombinant adeno-associated virus particles and / or cells of the present invention.

[0032] The present invention provides the use of the nucleic acid, AAV capsid protein, recombinant virus particle, recombinant adeno-associated virus particle, cell and / or pharmaceutical composition described herein in the preparation of a medicament for preventing or treating a disease.

[0033] The present invention provides a method for producing recombinant virus particles containing AAV capsid protein, the method comprising: providing cells in vitro with the nucleic acid of the present invention, the AAV Rep protein coding sequence, a recombinant vector genome containing heterologous nucleic acid, and a helper for producing productive infection, allowing the assembly of recombinant virus particles containing AAV capsid protein, and the encapsidation of the recombinant vector genome.

[0034] The present invention provides a method for producing recombinant AAV particles containing AAV capsid protein, the method comprising: providing cells in vitro with the nucleic acid of the present invention, AAV Rep protein coding sequence, rAAV genome containing heterologous nucleic acid, and helpers for producing productive infection, allowing the assembly of recombinant virus particles containing AAV capsid protein, and the encapsidation of the recombinant vector genome.

[0035] The present invention provides a method for delivering a nucleic acid of interest to a cell, the method comprising providing the cell with the nucleic acid, AAV capsid protein, recombinant virus particle, recombinant adeno-associated virus particle and / or pharmaceutical composition of the present invention.

[0036] The present invention provides a method for delivering a nucleic acid of interest to a mammalian individual, the method comprising: administering an effective dose of the nucleic acid, AAV capsid protein, recombinant viral particles, recombinant adeno-associated viral particles, cells and / or pharmaceutical composition of the present invention to the mammal.

[0037] The present invention also provides a method for identifying a viral vector, such as an AAV vector or an AAV capsid protein, having a certain tropism property of interest, the method comprising:

[0038] (a) providing a collection of viral vectors, such as AAV vectors, wherein each viral vector in the collection comprises:

[0039] (i) an AAV capsid protein comprising a capsid protein produced by shuffling two or more different AAV capsid protein coding sequences, wherein the amino acid sequences of the two or more different AAV capsid proteins differ by at least two amino acids; and (ii) a viral vector genome, such as an AAV viral genome, comprising a coding sequence encoding the AAV capsid protein described in (i), an AAV Rep protein coding sequence, and at least one terminal repeat sequence (e.g., 5' and / or 3' terminal repeat) that interacts with the AAV Rep protein, wherein the viral vector genome is encapsidated in the AAV capsid protein.

[0040] (b) administering the viral vector collection to a mammalian subject, and

[0041] (c) recovering a plurality of viral particles or viral vectors containing viral genomes encoding AAV capsid proteins from the target tissue, thereby identifying viral vectors or AAV capsid proteins having the tropism of interest.

[0042] The positive effects of the present invention are:

[0043] The present invention provides a group of novel AAV viral vectors, AAV capsid proteins, and virus particles comprising the AAV capsid proteins obtained by directed evolution and in vivo screening methods. Compared with the AAV viral vectors in the prior art, the AAV capsid viruses have interesting properties, such as targeting properties (higher liver tissue targeting) and / or neutralizing properties (for example, the ability to escape neutralizing antibodies).

[0044] The present disclosure is further described below in conjunction with the accompanying drawings and specific implementations, but is not intended to limit the present disclosure. Any equivalent replacement in the art made in accordance with the disclosure of this patent application shall fall within the scope of protection of this patent. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 . Restriction digestion patterns of randomly selected positive clones from plasmid library. 1-12 correspond to randomly selected positive clone samples, and M represents 5000bp DNA Marker.

[0046] Figure 2 .The number of AAV mutants appearing in the liver, skeletal muscle, and heart after two rounds of in vivo screening. A total of 370 positive clones were obtained after the first in vivo screening, and a total of 9 groups of novel AAV sequences with high frequency targeting the liver were obtained after the second in vivo screening.

[0047] Figure 3A-3R .New AAV-Cap sequence. The sequence diagram is divided into nucleotide sequence and encoded amino acid sequence.

[0048] Figures 4A-4F Comparison of different in vitro cell line infection (CAG-EGFP). Different AAV vectors were packaged into corresponding viruses carrying CAG-EGFP, and different cell lines were infected in vitro at different MOIs. Flow cytometry analysis was performed 48 hours later. Values ​​are mean ± SD.

[0049] Figures 5A-5E Comparison of in vitro infection of different cell lines (CAG-Luciferase). Different AAV vectors were packaged into corresponding viruses carrying CAG-Luciferase, and different cell lines were infected in vitro at MOI 500. Luciferase activity was detected after 48 hours. Values ​​are mean ± SD.

[0050] Figure 6 .The vector genome copy number in different tissues of mice after systemic injection of AAV vectors. Different AAV vectors were packaged into corresponding viruses carrying CAG-Luciferase and injected into the tail vein of mice at a dose of 1E+11vg for 2 weeks. The vector genome copy number in different tissues was compared. The values ​​are mean ± standard deviation.

[0051] Figures 7A-7E .Luciferase activity in different tissues of mice after systemic injection of AAV vectors. Comparison of Luciferase activity in different tissues of mice 2 weeks after different AAV vectors were packaged into corresponding viruses carrying CAG-Luciferase at a dose of 1E+11vg and injected into the tail vein of mice. Values ​​are mean ± standard deviation. DETAILED DESCRIPTION

[0052] The present invention provides a group of viral vectors comprising an AAV capsid with interesting properties obtained by a method for directing viral evolution through in vivo screening, for example, targeting properties and / or neutralizing properties (for example, the ability to escape neutralizing antibodies). The present invention also provides an AAV capsid and a viral particle comprising an AAV capsid.

[0053] The present invention will be described in more detail below. This specification is not intended to list in detail all different ways to implement the present invention. In addition, many variations of the various embodiments suggested by the present invention will be apparent to those skilled in the art without departing from the present invention. Therefore, the following description is intended to illustrate some specific embodiments of the present invention, rather than to describe in detail all permutations, combinations and variations thereof.

[0054] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. The terms used to describe the present invention in the present invention are only used to describe specific embodiments and are not intended to limit the present invention.

[0055] Unless otherwise indicated, standard methods known to those skilled in the art can be used to produce recombinant and synthetic polypeptides, antibodies or antigen-binding fragments thereof, manipulate nucleic acid sequences, produce transformed cells, construct recombinant AAV, modify capsid proteins, package vectors containing AAV rep and / or cap coding sequences, and transiently or stably transfect packaging cells. These techniques are well known to those skilled in the art, see SAMBROOK et al., MOLECULAR CLONING: A LABORATORY MANUAL 2nd Ed. (1989, Cold Spring Harbor, NY); FMAUSUBEL et al., CURRENT PROTOCOLS IN MOLECULARBIOLOGY (Green Publishing Associates, Inc. and John Wiley & Sons, Inc., New York).

[0056] All publications, patent applications, patents, nucleotide sequences, amino acid sequences, and other references mentioned herein are incorporated by reference in their entirety.

[0057] IDefinition

[0058] All amino acid positions in AAV capsid subunits throughout the specification and claims hereof are designated relative to the VP1 capsid subunit numbering.

[0059] In the description of the present invention and its claims, the singular forms "a", "an" and "the" include plural forms as well, unless the context clearly indicates otherwise.

[0060] In the present invention, "and / or" refers to any and all possible combinations including one or more of the described contents.

[0061] As used herein, the term "essentially comprises" in relation to a nucleic acid, protein or capsid structure means that the nucleic acid, protein or capsid structure contains any elements that may significantly alter the function of the nucleic acid, protein or capsid structure of interest, for example, the targeting properties or neutralizing properties of the protein or capsid or the protein or capsid encoded by the nucleic acid.

[0062] The term "adeno-associated virus (AAV)" in the context of the present invention includes, but is not limited to, AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, avian AAV, bovine AAV, canine AAV, equine AAV and ovine AAV, as well as any other AAV known or discovered later (BERNARD N. FIELDS et al., VIROLOGY, volume 2, chapter 69, 4th ed., Lippincott-Raven Publishers). Some additional AAV serotypes and branches that have been identified are also included in the term "AAV" in the present invention (Gao Guangping et al., 2004, J. Virology 78: 6381-6388).

[0063] The genome sequences of various AAVs and parvoviruses, as well as the sequences of ITRS, Rep proteins and capsid protein subunits are known in the art and can be found in the literature or in public databases. For example, in the GenBank database, Genbank accession numbers are NC 002077, NC 001401, NC 001729, NC 001863, NC 001829, NC 001862, NC000883, NC001701, NC 001510, AF063497, U89790, AF043303, AF028705, AF028704, J02275, J01901, J02275, X01457, AF288061, AH009962, AY028226, AY028223, NC 00135, NC 001540, AF513851, AY513852, and AY513853. 1966, the disclosures of which are incorporated herein by reference. In addition, Srivistava et al., 1983, J. Virology 45:555; Chiorini et al., 1998, J. Virology 71:6823; Chiorini et al., 1999, J. Virology 73:1309; Bantel-Schaal et al., 1999, J. Virology 73:939; Xiao et al., 1999, J. Virology 73:3994; Muramatsu et al., 1996, Virology 221:208; Shade et al., 1986, J. Virol. 58:921; Gao et al., 2002, Proc. Nat. Acad. Sci. USA 99:11854; International Patent Publications WO00 / 28061, WO 99 / 61601, WO 98 / 11244; U.S. Pat. No. 6,156,303; the disclosures of which are also incorporated herein by reference in their entirety. For an early description of the terminal repeat sequences of AAV1, AAV2, and AAV3, see Xiao, X, 1996, "Characterization of Adeno-associated virus (AAV) DNA replication and integration," Ph.D. Dissertation, University of Pittsburgh, Pittsburgh, Pa, the contents of which are incorporated herein by reference in their entirety.

[0064] A "shuffled" or "chimeric" AAV capsid coding sequence or AAV capsid protein is a nucleic acid sequence and an amino acid sequence produced by mixing two or more different AAV capsid protein sequences and combining portions of two or more capsid sequences. A "shuffled" or "chimeric" AAV virus particle comprises a "shuffled" or "chimeric" AAV capsid protein.

[0065] As used herein, the term "targeting" refers to the preferential entry of the virus into certain cell or tissue types and / or preferential interaction with the cell surface to facilitate its entry into certain cell or tissue types, optionally and preferably expressing sequences carried by the viral genome in the cell, for example, the recombinant virus expresses a heterologous nucleotide sequence. In the case of a recombinant AAV genome, gene expression of the viral genome can come from stably integrated proviruses and / or non-integrated episomes, as well as any other forms in which viral nucleic acids may occur within the cell.

[0066] The term "targeting property" refers to the transduction pattern of one or more target cells, tissues and / or organs. For example, some reorganized AAV capsids may show efficient transduction of liver, gonads and / or germ cells, some reorganized AAV capsids have only low levels of transduction of skeletal muscle, diaphragm muscle and / or cardiac muscle tissue, and typical reorganized AAV capsids have targeting characteristics of high transduction of liver and low transduction of skeletal muscle.

[0067] As used herein, "transduction" of cells by a viral vector refers to the transfer of genetic material into cells by the nucleic acid carried by the viral vector and subsequent transfer of genetic material by the viral vector.

[0068] As used herein, a "set" or "plurality" of viral particles, vectors, capsids, or capsid proteins means two or more, unless the context indicates otherwise.

[0069] Unless otherwise indicated, "efficient transduction" or "effective targeting" or similar terms can be determined by reference to a suitable control, for example, at least 50%, 60%, 70%, 80%, 85%, 90%, 95% or more transduction or targeting relative to a control.

[0070] Similarly, whether a virus "does not effectively transduce" or "does not effectively target" a target cell or tissue can be determined by reference to an appropriate control. In specific embodiments, the viral vector does not effectively transduce skeletal muscle or cardiomyocytes. In specific embodiments, the ineffective transduction of a tissue is 20% or less, 10% or less, 5% or less, 1% or less, or 0.1% or less of the transduction level of an effectively transduced tissue.

[0071] As used herein, unless otherwise indicated, the term "polypeptide" includes peptides and proteins.

[0072] "Nucleic acid" or "nucleotide sequence" is a nucleotide base sequence, which can be RNA, DNA or DNA-RNA hybrid sequence, including naturally occurring and non-naturally occurring nucleotides, but is preferably a single-stranded or double-stranded DNA sequence.

[0073] As used herein, an "isolated" nucleic acid or nucleic acid sequence refers to a nucleic acid or nucleic acid sequence that is separated from at least some other components of a naturally occurring organism or virus, such as cellular or viral structural components or other polypeptides or nucleic acids with which the nucleic acid or nucleic acid sequence is normally associated.

[0074] Likewise, an "isolated" polypeptide refers to a polypeptide that is separated from at least some other components of a naturally occurring organism or virus, such as cellular or viral structural components or other polypeptides or nucleic acids with which the polypeptide is normally associated.

[0075] The term "treatment" or grammatically equivalent terms refers to a reduction in the severity of the subject's condition or at least a partial improvement or amelioration, and / or at least a alleviation or reduction of one clinical symptom, and / or a delay in the progression of the condition and / or the prevention or delay of the onset of a disease or disorder. The term "treatment" herein also includes prophylactic treatment of the subject, for example, prevention of infection, cancer or the onset of disease. As used herein, the term "prevention" and its grammatically equivalent terms include any type of treatment that prevents the incidence of the condition, delays the onset and / or progression of the condition, and / or alleviates symptoms associated with the condition. Therefore, unless the context indicates otherwise, the term "treatment" or grammatically equivalent terms refers to preventive and therapeutic methods or regimens.

[0076] As used herein, an "effective" dose is a dose sufficient to obtain some improvement or benefit to a subject. In other words, an "effective" dose is a dose that relieves or reduces at least one clinical symptom of a subject. Those skilled in the art will understand that the therapeutic effect does not have to be complete or curative, as long as the subject obtains an improvement or benefit.

[0077] A "heterologous nucleotide sequence" or "heterologous nucleic acid" is generally not a sequence that occurs naturally in a virus. Typically, a heterologous nucleic acid or nucleotide sequence comprises an open reading frame encoding a polypeptide and / or a non-translated RNA.

[0078] A "therapeutic polypeptide" may be a polypeptide that can alleviate or reduce symptoms caused by protein deficiency or defects in cells or subjects. In addition, a "therapeutic polypeptide" may be a polypeptide that brings benefits to subjects in other ways, such as anti-cancer effects or improved transplant survival rates.

[0079] As used herein, "vector", "viral vector", "delivery vector" generally refers to a viral particle as a nucleic acid delivery vehicle, which includes a viral nucleic acid, i.e., a vector genome, packaged in a virion. The viral vector according to the present invention includes a chimeric AAV capsid of the present invention and can package an AAV or recombinant AAV genome or any other nucleic acid including a viral nucleic acid. Alternatively, in some cases, the terms "vector", "viral vector", "delivery vector" may be used to refer to a vector genome in the absence of a viral particle and / or to a viral capsid as a transporter to deliver molecules associated with or packaged within the capsid.

[0080] A "recombinant AAV vector genome" or "rAAV genome" is an AAV genome that contains at least one inverted terminal repeat and one or more heterologous nucleotide sequences. rAAV vectors typically retain the 145 base terminal repeats (TRs) in a cis structure to produce viruses; however, modified AAV-TRs and non-AAV-TRs can also be used for this purpose. All other viral sequences are dispensable and can be provided in trans (Muzyczka, 1992, curr-topicsmicrobial.Immunol.158:97). rAAV vectors may optionally contain two TRs, such as AAV TRs, which are typically located at the 5' and 3' ends of the heterologous nucleotide sequence, but do not have to be adjacent to it. TRs can be the same or different. The vector genome may also contain a TR at the 3' or 5' end.

[0081] The term "terminal repeat" or "tr" includes any viral terminal repeat or synthetic sequence that forms a hairpin structure and functions as an inverted terminal repeat, i.e., mediates desired functions such as replication, viral packaging, integration, and / or proviral rescue. TR can be AAV TR or non-AAV TR. For example, non-AAV TR sequences can be other parvoviruses, such as canine parvovirus CPV, mouse parvovirus MVM, human parvovirus B-19, or SV40 hairpins as SV40 replication sources, and can be further modified by truncation, substitution, deletion, insertion. In addition, TR can be partially or completely synthetic, such as the "double D sequence" described in U.S. Pat. No. 5,478,745.

[0082] "AAV-terminal repeats" or "AAV TRs" can be from any AAV, including but not limited to serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or any other known or later discovered AAV. As long as the terminal repeats mediate the desired function, such as replication, viral packaging, integration, and / or proviral rescue, etc., it is not necessary to have the native terminal repeat sequence, for example, the native AAV TR sequence can be altered by insertions, deletions, truncations, and / or missense mutations.

[0083] The terms "recombinant AAV particle" and "recombinant AAV particle" are used interchangeably. A "recombinant AAV particle" or "recombinant AAV particle" comprises a recombinant AAV vector genome packaged in an AAV capsid.

[0084] "Substantially retaining" a property means retaining at least about 75%, 85%, 90%, 95%, 97%, 98%, 99% or 100% of the property, for example, activity or other measurable property.

[0085] II. Chimeric AAV capsids identified by directed evolution and in vivo screening

[0086] The inventors have identified "chimeric" or "shuffled" AAV capsid structures with interesting characteristics, such as targeting properties and / or neutralization properties. In specific embodiments, the chimeric AAV capsids exhibit efficient transduction of the liver and / or inefficient transduction of skeletal and / or cardiac muscle.

[0087] Thus, in some embodiments, the present invention provides chimeric AAV capsids comprising, consisting essentially of, or consisting of the following amino acid sequence: Figure 3B , 3D , 3F, 3H, 3J, 3L, 3N, 3P or 3R.

[0088] In a specific embodiment, the chimeric AAV capsid protein may comprise or consist essentially of Figure 3B , Figure 3D , Figure 3F , Figure 3H , Figure 3J , Figure 3L , Figure 3N , Figure 3P or Figure 3R The amino acid sequences shown in the figures, or consist of the amino acid sequences shown in these figures.

[0089] Furthermore, in non-limiting embodiments, the chimeric AAV capsid protein of the invention may be encoded by a nucleic acid comprising or consisting essentially of Figure 3A , Figure 3C , Figure 3E , Figure 3G , Fig. 3I , Figure 3K , Figure 3M , Fig.3O or Figure 3QThe nucleotide sequences shown in the figures, or consisting of the nucleotide sequences shown in these figures; or a nucleotide sequence encoding an AAV capsid or capsid protein encoded by any of the above nucleotide sequences, but different from the above nucleotide sequences due to the degeneracy of the codons. All amino acid position designations in the present specification and the appended claims are related to VP1 numbering. Those skilled in the art will understand that due to the overlap of AAV capsid coding sequences, the modifications described herein may also result in changes in the VP2 and / or VP3 capsid subunits.

[0090] The present invention also provides chimeric AAV capsid proteins comprising, substantially comprising, or consisting of the following amino acid sequence. Methods for evaluating biological properties such as viral transduction and / or antibody neutralization are well known in the art.

[0091] Conservative amino acid substitutions are known in the art. In a specific embodiment, conservative amino acid substitutions include one or more substitutions in the following group: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and / or phenylalanine, tyrosine.

[0092] It is obvious to those skilled in the art that Figure 3B , 3D The amino acid sequences of the chimeric AAV capsid proteins shown in , 3F, 3H, 3J, 3L, 3N, 3P, and 3R are applied to any other modifications known in the art, and further modified to obtain the desired properties. For example, the AAV2 capsid sequence is mutated to R484E and R585E, which improves the transduction of the AAV vector to the heart (Muller et al., 2006, Cardiovascular Research 70: 70-78). As a further non-limiting modification possibility, the capsid protein is modified to include a targeting sequence or a sequence that facilitates purification and / or detection, for example, the capsid protein can be fused with all or part of glutathione-S-transferase, maltose binding protein, heparin / heparin sulfate binding domain, poly-HIS, ligand and / or reporter protein, immunoglobulin Fc fragment, single-chain antibody, hemagglutinin, C-MYC, tag epitope, etc. to form a fusion protein. Methods for inserting targeting peptides into AAV capsids are known in the art, for example, International Patent WO00 / 28004; Nicklin et al., 2001, Molecular Therapy 474-181; White et al., 2004, Circulation 109:513-319; Muller et al., 2003, Nature Biotech 21:1040-1046.

[0093] The virus of the present invention may further comprise a dual viral genome as described in International Patent WO01 / 92551 and US Patent US7465583.

[0094] The present invention also provides a recombinant virus particle comprising the chimeric AAV capsid protein of the present invention, wherein the vector genome is encapsidated in the virus particle, preferably the AAV vector genome. In a specific embodiment, the present invention provides a recombinant AAV particle comprising the chimeric AAV capsid protein of the present invention, wherein the AAV vector genome is encapsidated in the AAV capsid.

[0095] In a specific embodiment, the virus is a recombinant vector comprising a heterologous nucleic acid of interest. Therefore, the present invention can be used to deliver nucleic acids to cells in vitro and in vivo. In a representative embodiment, the recombinant vector of the present invention is used to deliver or transfer nucleic acids to animal cells, preferably mammalian cells.

[0096] Any heterologous nucleotide sequence can be delivered by the viral vector of the present invention. Nucleic acids of interest include nucleic acids encoding polypeptides, optionally therapeutic polypeptides and / or immunogenic polypeptides.

[0097] Therapeutic polypeptides include, but are not limited to, insulin, glucagon, growth hormone, parathyroid hormone, growth hormone releasing factor, follicle stimulating hormone, luteinizing hormone, human chorionic gonadotropin, vascular endothelial growth factor, angiopoietin, angiostatin, granulocyte colony stimulating factor, erythropoietin, connective tissue growth factor, basic fibroblast growth factor, acidic fibroblast growth factor, epidermal growth factor, platelet-derived growth factor, insulin growth factor I and II, any of the transforming growth factor α superfamily, activin, inhibin, any of the bone morphogenetic proteins, nerve growth factor, brain-derived neurotrophic factor, neurotrophins NT-3 and NT-4 / 5, ciliary neurotrophic factor, glial cell line-derived neurotrophic factor, aggrecan, any of the semaphorin / disruptor family, netrin-1 and netrin-2, hepatocyte growth factor, ephrin, noggin, sonic Hedgehog protein and tyrosine hydroxylase, thrombopoietin, interleukins IL-1 to IL-25, monocyte chemoattractant protein, leukemia inhibitory factor, granulocyte-macrophage colony stimulating factor, Fas ligand, tumor necrosis factor alpha and beta, interferon alpha, beta and gamma, stem cell factor, flk-2 / flt3 ligand.Gene products produced by the immune system can also be used in the present invention, including but not limited to immunoglobulins IgG, IgM, IgA, IgD and IgE, chimeric immunoglobulins, humanized antibodies, single chain antibodies, T cell receptors, chimeric T cell receptors, single chain T cell receptors, class I and class II MHC molecules and modified immunoglobulins, complement regulatory proteins, membrane cofactor proteins, decay accelerating factors, CR1, CF2 and CD59, low density lipoprotein receptors, high density lipoprotein receptors, very low density lipoprotein receptors and scavenger receptors, glucocorticoid receptors and estrogen receptors, vitamin D receptor and other nuclear receptors, jun / fos, max, mad, serum effector factors, AP-1, AP2, myb, MyoD and myogenic proteins, TFE3, E2F, ATF1, ATF2, ATF3, ATF4, ZF5, NFAT, CREB, HNF-4, C / EBP, CCAAT-box binding protein, interfering kinase, Wilms tumor protein, ETS-binding protein, STAT, GATA-box binding protein and forkhead protein family of winged helix proteins, carbamoyl synthetase 1, ornithine transcarbamylase, argininosuccinate synthetase, argininosuccinate lyase, arginase, fumarylacetoacetate hydrolase, phenylalanine hydroxylase, alpha-1 antitrypsin, glucosidase, glucose-6-phosphatase, porphobilinogen deaminase, cystathionine B synthase, branched-chain ketoacid decarboxylase enzymes, isovaleryl-CoA dehydrogenase, propionyl-CoA carboxylase, methylmalonyl-CoA mutase, glutaryl-CoA dehydrogenase, insulin, β-glucosidase, pyruvate carboxylate, liver phosphorylase, phosphorylase kinase, glycine decarboxylase, H-protein, T-protein, cystic fibrosis transmembrane conductance regulator, anti-trophic protein, α-galactosidase, β-galactosidase, lysosomal enzymes, coagulation factors, and any other polypeptides having a therapeutic effect in an individual in need thereof.

[0098] The heterologous nucleotide sequence encoding a polypeptide includes a sequence encoding a reporter gene polypeptide. The polypeptides encoded by reporter genes known in the art include, but are not limited to, green fluorescent protein, β-galactosidase, alkaline phosphatase, luciferase, and chloramphenicol acetyltransferase.

[0099] On the other hand, the heterologous nucleic acid can encode an antisense oligonucleotide, including ribozymes, interfering RNA, including small interfering RNA that mediates gene silencing (Sharp et al., 2000, Science 287:2431), microRNA, other non-translated functional RNAs, such as "guide" RNAS (Gorman et al., 1998, Proc. Nat. Acad. Sci. USA 95:4929; U.S. Pat. No. 5,869,248), etc.

[0100] It is known in the art that antisense nucleic acids and inhibitory RNA sequences can induce "exon skipping." Thus, the heterologous nucleic acid can encode an antisense nucleic acid or inhibitory RNA that induces appropriate exon skipping.

[0101] Ribozymes are RNA protein complexes that cleave nucleic acids in a site-specific manner. Ribozymes have specific catalytic domains and have endonuclease activity (Kim et al., 1987, Proc. Natl. Acad. Sci. USA 84:8788; Gerlach et al., 1987, Nature 328:802; Forster and Symons, 1987, Cell 49:211).

[0102] MicroRNAs are natural cellular RNA molecules that regulate the expression of multiple genes by controlling the stability of mRNA. Overexpression or reduction of specific microRNAs can be used to treat functional disorders and has been shown to be effective in many disease states and disease animal models (Couzin, 2008, Science 319: 1782-1784). Chimeric AAV can be used to introduce microRNA into cells, tissues and subjects for the treatment of genetic and acquired diseases, or to enhance the function of certain tissues and promote their growth. For example, mir-1, mir-133, mir-206 and / or mir-208 can be used to treat heart and skeletal muscle diseases (Chen et al., 2006, Genet 38: 228-233; van Rooij et al., 2008, Trends Genet. 24: 159-166), and microRNA can also be used to regulate the immune system after gene delivery (Brown et al., 2007, Blood 110: 4144-4152).

[0103] The term "antisense oligonucleotide", including "antisense RNA", used herein refers to a nucleic acid that is complementary to and specifically hybridizes to a specific DNA or RNA sequence. Antisense oligonucleotides and nucleic acids encoding the same can be prepared according to conventional techniques.

[0104] Those skilled in the art will appreciate that antisense oligonucleotides need not be completely complementary to the target sequence, as long as the sequence similarity is sufficient to allow the antisense nucleotide sequence to specifically hybridize with the target sequence and reduce the production of protein products, for example, the similarity is at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more. In order to determine the specificity of hybridization, hybridization of such oligonucleotides to the target sequence can be carried out under weak, medium, or even stringent conditions.

[0105] Antisense oligonucleotides can be synthesized by chemical synthesis and enzyme-bound reactions using procedures known in the art. For example, an antisense oligonucleotide can be chemically synthesized using naturally occurring nucleotides or various modified nucleotides, the purpose of which is to increase the biological stability of the molecule and / or to increase the stability of the double strand formed between the antisense strand and the sense strand, for example, thiophosphate derivatives and acridine-substituted nucleotides can be used.

[0106] Modified nucleotides that can be used to generate antisense oligonucleotides include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, β-D-galactosylquinoline, inosine, N6-isopentenyllysine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytidine, 5-methylcytosine, N6-adenine Purine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, β-D-mannosylquinoline, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenylamine, uracil-5-oxyacetic acid, quinoline, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methyl ester, uracil-5-oxyacetic acid, 5-methyl-2-thiouracil, and 2,6-diaminopurine, etc.

[0107] Antisense oligonucleotides can be chemically modified to covalently bind to another molecule. For example, antisense oligonucleotides can be conjugated to a molecule that facilitates delivery to cells of interest, enhances absorption by the nasal mucosa, provides a detectable marker, increases the bioavailability of the oligonucleotide, improves the stability of the oligonucleotide, or improves formulation or pharmacokinetic properties, etc. Conjugated molecules include, but are not limited to, cholesterol, lipids, polyamines, polyamides, polyesters, reporter molecules, biotin, dyes, polyethylene glycol, human serum albumin, enzymes, antibodies or antibody fragments, or cell receptor ligands.

[0108] Other modifications of nucleic acids to improve stability, nuclease resistance, bioavailability, formulation characteristics and / or pharmacokinetic properties are also known in the art.

[0109] RNA interference is a mechanism of post-transcriptional gene silencing, which imports double-stranded RNA (DsRNA) corresponding to the target sequence into cells or organisms, resulting in the degradation of corresponding mRNA. The mechanism of RNAi to achieve gene silencing has been reported in multiple review articles (Sharp et al., 2001, Genes Dcv 15:485-490; Hammond et al., 2001, Nature Rev Gen 2:110-119). Before gene expression is restored, the RNAi effect persists in multiple cell divisions. Therefore, RNAi is an effective method for targeted knockout at the RNA level. RNAi has been shown to be successful in human cells, including human embryonic kidney and HeLa cells (Elbashir et al., 2001, Nature 411:494-498). It has been demonstrated that short synthetic dsRNAs of approximately 21 nucleotides, also known as "short interfering RNAs," can mediate silencing of mammalian cells without triggering an antiviral response (Elbashir et al., 2001, Nature 411:494-498; Caplen et al., 2001, Proc. Nat Acad. Sci. 98:9742).

[0110] RNAi molecules can be short hairpin RNA (Paddison et al., 2002, PNAS USA 99: 1443-1448), which are processed into 20-25 length siRNA molecules by RNaseIII digestion in cells. ShRNA usually has a stem-loop structure, i.e., two inverted repeat sequences are connected by a short spacer sequence.

[0111] Methods for generating RNAi include chemical synthesis, in vitro transcription, in vitro or in vivo digestion of long dsRNA by Dicer, in vivo expression by delivery vectors, and in vivo expression of RNAi expression cassettes derived from PCR.

[0112] The antisense region of the RNAi molecule can be completely complementary to the target sequence, but as long as it specifically hybridizes to the target sequence and reduces the production of the protein product, such as at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more, it does not need to be completely complementary to the target sequence. In some embodiments, the hybridization of the oligonucleotide to the target sequence can be carried out under weak stringency, medium stringency or even high stringency conditions as defined above.

[0113] In other embodiments, the antisense region of RNAi has at least about 60%, 70%, 80%, 90%, 95%, 97%, 98% or higher sequence identity with the target sequence, and reduces the production of protein products by at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more. In certain embodiments, compared with the target sequence, the antisense region comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mismatches. Mismatches are usually more acceptable at the ends of the dsRNA than in the central part. The RNAi molecule can comprise modified sugars, modified nucleotides, backbone connections and other modifications of the above-mentioned antisense oligonucleotides.

[0114] The present invention also provides recombinant viral vectors expressing immunogenic polypeptides. The heterologous nucleic acid may encode any immunogen of interest known in the art, including but not limited to from human immunodeficiency virus, influenza virus, Gag protein, tumor antigens, cancer antigens, bacterial antigens, viral antigens, etc. Alternatively, the immunogen may be presented in a viral capsid, for example, by covalent modification and binding to the viral shell.

[0115] Parvoviruses are known in the art for use as vaccines (US5916563, US5905040, US5882652). The antigen may be present in the viral capsid, or the antigen may be expressed from a heterologous nucleic acid introduced into the genome of a recombinant vector.

[0116] The immunogenic polypeptide or immunogen can be any polypeptide suitable for protecting a subject from disease, including but not limited to microbial, bacterial, protozoan, parasitic, fungal and viral diseases. The immunogen can be a promyxovirus immunogen, for example, an influenza virus immunogen, an influenza virus hemagglutinin surface protein or an influenza virus nucleoprotein gene; or a lentivirus immunogen, for example, an equine infectious anemia virus immunogen, a simian immunodeficiency virus immunogen or a human immunodeficiency virus immunogen; or an arenavirus immunogen, for example, a Lassa fever virus immunogen; or a poxvirus immunogen, a flavivirus immunogen, a filovirus immunogen, a bunyavirus immunogen, a coronavirus immunogen or a severe acute respiratory syndrome immunogen. The immunogen can also be a polio immunogen, a herpes immunogen, a mumps immunogen, a measles immunogen, a rubella immunogen, a diphtheria toxin or other diphtheria immunogen, a pertussis antigen, a hepatitis immunogen or any other vaccine immunogen known in the art.

[0117] Alternatively, the immunogen may be any tumor or cancer cell antigen. Optionally, the tumor or cancer antigen is expressed on the surface of a cancer cell. Exemplary cancer and tumor antigens include, but are not limited to, BRCA1 gene products, BRCA2 gene products, GP100, tyrosinase, GAGE-1 / 2, RAGE, NY-ESO-1, CDK-4, 3-catenin, MUM-1, caspase-8, HPVE, SART-1, PRAME, p15, melanoma tumor antigens, HER-2 / neu gene products, estrogen receptor, milk fat globulin, p53 tumor suppressor protein, mucin antigens, telomerase, nuclear matrix protein, prostatic acid phosphatase, papillomavirus antigens, and antigens associated with the following cancers, including melanoma, adenocarcinoma, thymoma, sarcoma, lung cancer, liver cancer, colorectal cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukemia, uterine cancer, breast cancer, prostate cancer, ovarian cancer, cervical cancer, bladder cancer, kidney cancer, pancreatic cancer, brain cancer, kidney cancer, stomach cancer, esophageal cancer, and head and neck cancer.

[0118] Alternatively, the heterologous nucleotide sequence may encode any polypeptide produced in cells in vitro or in vivo. For example, a viral vector may be introduced into cultured cells and the expressed protein product isolated therefrom.

[0119] Those skilled in the art will appreciate that the heterologous nucleic acid of interest may be operably linked to appropriate control sequences. For example, the heterologous nucleic acid may be linked to expression control elements such as transcriptional and translational control signals, replication origins, polyadenylation signals, internal ribosome entry sites, promoters, enhancers, and the like.

[0120] Those skilled in the art will further appreciate that various promoter / enhancer elements may be used, depending on the desired expression level and tissue-specific expression. Promoters / enhancers may be constitutive or inducible, depending on the desired expression pattern. Promoters / enhancers may be native or foreign, and may be natural or synthetic sequences.

[0121] The promoter / enhancer element can be intrinsic to the target cell or subject, or it can be intrinsic to the heterologous nucleic acid sequence. The promoter / enhancer element is generally selected so that it functions in the target cell of interest. In a representative embodiment, the promoter / enhancer element is a mammalian promoter / enhancer element, and the promoter / enhancer element can be constitutive or inducible.

[0122] Inducible expression control elements are generally used in applications where it is necessary to regulate the overexpression of heterologous nucleic acid sequences. Inducible promoter / enhancer elements for gene delivery can be tissue-specific or tissue-preferred promoter / enhancer elements, and include muscle-specific or preferred, neural tissue-specific or preferred, eye (including retina-specific and corneal-specific) specific or preferred, liver-specific or preferred, bone marrow-specific or preferred, pancreas-specific or preferred, spleen-specific or preferred, lung-specific or preferred. Other inducible promoter / enhancer elements include hormone-inducible and metal-inducible elements. Exemplary inducible promoter / enhancer elements include, but are not limited to, Tet on / off elements, RU486 inducible promoters, rapamycin-inducible promoters, and metallothionein promoters.

[0123] In embodiments where heterologous nucleic acid sequences are transcribed and translated in target cells, specific initiation signals are generally used to efficiently translate the inserted protein coding sequences. These exogenous translation control sequences, which may include the ATG initiation codon and adjacent sequences, can be of various forms, both natural and synthetic.

[0124] The present invention provides chimeric AAV particles comprising a chimeric AAV capsid and an AAV genome. The present invention also provides a collection or library of said chimeric AAV particles, wherein said collection or library comprises 2 or more, 10 or more, 50 or more, 1 ... 2 or more, 10 3 or more, 10 4 or more, 10 5 or more, or 10 6 or more different sequences.

[0125] The present invention also includes "empty" capsid particles, which contain, consist of or are essentially composed of the chimeric AAV capsid protein of the present invention, as described in U.S. Pat. No. 5,863,541. The chimeric AAV capsid of the present invention can be used as a "capsid carrier", and the molecules that can be covalently linked, bound or packaged and transferred to cells include DNA, RNA, lipids, carbohydrates, polypeptides, small organic molecules, or a combination of these molecules. In addition, the molecule can be associated with the outside of the viral capsid so as to transfer the molecule to the target cell of the host. In one embodiment of the present invention, the molecule is covalently linked to the capsid protein. Methods for covalently linking molecules are well known to those skilled in the art.

[0126] The virus capsid of the present invention can also be used to improve antibodies against the new capsid structure. As another option, the foreign amino acid sequence can be inserted into the virus capsid to present the antigen to cells, such as administered to a subject to generate an immune response to the foreign amino acid sequence.

[0127] The present invention also provides nucleic acids encoding the chimeric capsid proteins of the present invention. Further provided are vectors comprising the nucleic acids and cells comprising the nucleic acids and / or vectors of the present invention. For example, the nucleic acids, vectors and cells can be used as reagents for producing the viral vectors described herein.

[0128] In an exemplary embodiment, the present invention provides an encoding Figure 3B , 3D , 3F, 3H, 3J, 3L, 3N, 3P, or 3R. Representative nucleic acid sequences include or essentially include: Figure 3A (L1) Figure 3C (L4), Figure 3E (L10), Figure 3G (L52), Fig. 3I (L58), Figure 3K (L84), Figure 3M (L37), Fig.3O (L107) or Figure 3Q (L57) is a nucleotide sequence shown in, or is composed of the nucleotide sequences shown in these figures, or encodes a nucleotide sequence of an AAV capsid or capsid protein encoded by any of the above nucleotide sequences, but is different from the above nucleotide sequences due to the degeneracy of codons, which allows different nucleic acid sequences to encode the same AAV capsid.

[0129] The present invention also provides nucleic acids encoding variants and fusion proteins of the above-mentioned AAV capsid proteins. In specific embodiments, the nucleic acid hybridizes with the complementary strand of the nucleic acid sequence specifically disclosed herein under standard conditions known to those skilled in the art to encode variant capsid proteins. The nucleic acid sequences specifically disclosed herein are described in Figure 3A , Figure 3C , Figure 3E , Figure 3G , Fig. 3I , Figure 3K , Figure 3M , Fig.3O or Figure 3Q Optionally, the variant capsid protein substantially retains Figure 3A , Figure 3C , Figure 3E , Figure 3G , Fig. 3I , Figure 3K , Figure 3M , Fig.3O or Figure 3Q At least one property of the capsid protein encoded by the nucleic acid sequence shown in the embodiment of the present invention. For example, the virus particle of the variant capsid protein can substantially retain the virus particle containing the capsid protein composed of Figure 3A , Figure 3C , Figure 3E , Figure 3G , Fig. 3I , Figure 3K, Figure 3M , Fig.3O , Figure 3Q The nucleic acid coding sequence shown encodes the targeting characteristics of the viral particles of the capsid protein. The hybridization of this sequence can be carried out under weak, medium or even stringent conditions (Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual 2d Ed, Cold Spring Harbor Laboratory).

[0130] As known in the art, many different programs can be used to determine whether a nucleic acid or polypeptide has a percent identity or similarity with a known sequence. Percentage designations used herein refer to when a nucleic acid or its fragment has a specified percentage with another nucleic acid when compared with other nucleic acids using BLASTN, which program can be obtained from the U.S. National Center for Biotechnology Information (NCBI) via the Internet.

[0131] When referring to polypeptides, the percentage identity or similarity indicates that the polypeptide exhibits a specific percentage of identity or similarity when compared to another protein or a portion thereof over a common length determined using BLASTP. This can also be obtained from the National Center for Biotechnology Information (NCBI) via the Internet. The percentage of identity or similarity of polypeptides is usually obtained using sequence analysis software, for example, see the sequence analysis software package of the Genetics Computer Group at the University of Wisconsin Biotechnology Center. Protein analysis software uses the homology of various substitutions, deletions and other modifications to match similar sequences. Conservative substitutions generally include substitutions in the following categories: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; phenylalanine, tyrosine.

[0132] In a specific embodiment, the nucleic acid may comprise, consist of or consist essentially of a vector such as a plasmid, a phage, a viral vector, a bacterial artificial chromosome or a yeast artificial chromosome, but is not limited to a vector such as a plasmid, a phage, a viral vector, a bacterial artificial chromosome or a yeast artificial chromosome. The viral vector includes but is not limited to an adeno-associated viral vector, an adenoviral vector, a herpes virus vector, a baculovirus vector or a hybrid viral vector.

[0133] In some embodiments, the nucleic acid encoding the chimeric AAV capsid protein further comprises an AAV Rep protein coding sequence.

[0134] The invention also provides cells that stably contain the nucleic acid of the invention. For example, the nucleic acid can be stably transferred into the genome of the cell, or can be stably maintained in episomal form, for example, an "EBV-based nuclear episome".

[0135] The nucleic acid can be inserted into a delivery vector, for example, a viral delivery vector. For example, the nucleic acid of the invention can be encapsulated in an AAV particle, an adenoviral particle, a herpes virus particle, a baculovirus particle, or any other suitable virus particle.

[0136] Furthermore, the nucleic acid may be operably linked to a promoter element.

[0137] The present invention also provides a method for producing the viral vector of the present invention. In a representative embodiment, the present invention provides a method for producing a recombinant viral vector, the method comprising providing to cells in vitro, including heterologous nucleic acid and a signal sequence sufficient to package the AAV template into viral particles, for example, an AAV terminal repeat sequence; and also including an AAV sequence sufficient to replicate and package the template into viral particles, such as an AAV Rep sequence, and a sequence encoding the AAV capsid of the present invention. The method further comprises the step of collecting viral particles from the cells, and the viral particles can be collected from the culture medium and / or lysed cells.

[0138] In an illustrative embodiment, the present invention provides a method for preparing recombinant AAV particles comprising an AAV capsid, the method comprising: providing a nucleic acid encoding a chimeric AAV capsid of the present invention, an AAV Rep coding sequence, an AAV vector genome comprising a heterologous nucleic acid, and auxiliary factors for producing infectious AAV to cells in vitro, allowing the AAV vector genome to be encapsulated in the AAV capsid and completing the assembly of the AAV particles.

[0139] The cell is typically a cell that allows the AAV virus to replicate. Any suitable cell known in the art can be used, including but not limited to one or more of the HEK293 cell line, HEK293T cell line, HEK293A cell line, HEK293S cell line, HEK293FT cell line, HEK293F cell line, HEK293H cell line, HeLa cell line, SF9 cell line, SF21 cell line, SF900 cell line, and BHK cell line.

[0140] AAV replication and capsid sequences can be provided by any method known in the art. Current methods generally express AAV rep and cap genes on a single plasmid. AAV replication and packaging sequences do not need to be provided together. AAV rep and / or cap gene sequences can be provided by any viral or non-viral vector. For example, rep and / or cap gene sequences can be provided by hybrid adenovirus or herpes virus vectors. EBV vectors can also be used to express AAV cap and / or rep gene sequences. As another option, rep and / or cap gene sequences can be stably present in cells, in a free or integrated state.

[0141] Typically the AAV rep and / or cap gene sequences are not surrounded by AAV packaging sequences to prevent rescue and / or packaging of these sequences.

[0142] The template or vector genome can be provided to the cell using any method known in the art. The template or vector genome can be provided by a non-viral vector or a viral vector. In a specific embodiment, the template or vector genome is provided by a herpes virus or an adenovirus vector. Baculovirus vectors and EBV vectors can also be used to deliver the template or vector genome. In another representative embodiment, the template or vector genome is provided by a replicated rAAV virus. In other embodiments, the AAV provirus is stably integrated into the chromosome of the cell.

[0143] In order to obtain the maximum viral titer, cells are usually provided with helper viruses, such as adenovirus or herpes virus, which are necessary for the production of infectious AAV. The helper virus sequences necessary for AAV replication known in the art are usually provided by helper adenovirus or herpes virus vectors. Alternatively, adenovirus or herpes virus sequences can be provided by another non-viral or viral vector (Ferrari et al., 1997, Nature Med. 3: 1295). In addition, the helper virus function can be provided by the integration of helper genes into the chromosomes of the packaging cells or maintained as a stable extrachromosomal element.

[0144] Those skilled in the art will appreciate that it may be advantageous to provide the AAV replication and capsid sequences and the helper virus sequences on a single helper construct. The helper construct may be a non-viral or viral construct, and may also be a hybrid adenovirus or hybrid herpes virus containing the AAV rep / cap gene sequences.

[0145] In a specific embodiment, the AAV rep and / or cap gene sequences and the adenovirus helper sequences are provided by a single adenovirus helper vector. This vector further comprises a rAAV genome template. The AAV rep and / or cap sequences and / or the rAAV template can be inserted into a deletion region of the adenovirus, for example, the Ela or E3 region.

[0146] In another embodiment, AAV rep and / or cap sequences and adenovirus helper sequences are provided by a single adenovirus helper vector. The rAAV genome template is provided by a plasmid. In another illustrative embodiment, AAV rep and / or cap sequences and adenovirus helper sequences are provided by a single adenovirus helper vector, and the rAAV genome template is integrated into the cell as a precursor. Alternatively, the rAAV template is provided by an EBV vector maintained in the cell as an extrachromosomal element. In another exemplary embodiment, AAV rep and / or cap sequences and adenovirus helper sequences are provided by a single adenovirus vector. The rAAV genome template is provided as a separate replicating viral vector. For example, the rAAV template can be provided by rAAV particles or a second recombinant adenovirus particle.

[0147] Herpes viruses can also be used as helper viruses in AAV packaging methods.

[0148] As another alternative, the viral vectors of the present invention can use baculovirus vectors to deliver the rep and / or cap genes and the rAAV template in insect cells (Urabe et al., 2002, Human Gene Therapy 13:1935-1943).

[0149] Other methods for producing AAV may also use stably transformed packaging cells (see U.S. Pat. No. 5,658,785).

[0150] AAV vectors without helper virus contamination can be obtained by any method known in the art. For example, AAV and helper virus can be easily distinguished according to size. AAV can also be separated from helper virus according to affinity for heparin substrate. In a representative embodiment, a replication-deficient helper virus is used so that any contaminating helper virus cannot replicate. As another option, a helper adenovirus lacking late gene expression can be used, because only adenovirus early gene expression mediates the packaging of AAV virus. Adenovirus mutants defective for late gene expression are known in the art, for example, TS100K and TS149 adenovirus mutants.

[0151] The packaging method of the present invention can be used to produce high titer virus particles. In a specific embodiment, the titer of the virus stock solution is at least about 10 5 Tu / ml, at least about 10 6 Tu / ml, at least about 10 7 Tu / ml, at least about 10 8 Tu / ml, at least about 10 9 Tu / ml, at least about 10 10 Tu / ml.

[0152] The novel capsid proteins and capsid structures can be used to generate antibodies, for example for diagnostic or therapeutic purposes or as research reagents. Therefore, the present invention also provides antibodies against the novel capsid proteins of the present invention.

[0153] The term "antibody" or "antibody fragment" as used herein refers to all types of immunoglobulins, including IgG, IgM, IgA, IgD and IgE. Antibodies can be monoclonal or polyclonal, and can be derived from any species, including mice, rats, rabbits, horses, goats, sheep, chickens, monkeys, alpacas or humans, or can be chimeric antibodies, humanized antibodies, human antibodies. Antibodies can be recombinant monoclonal antibodies, or screened from phage libraries, yeast libraries, mammalian cell display libraries.

[0154] Antibody fragments included within the scope of the present invention include Fab, F(ab') 2 and Fc fragments, and corresponding fragments obtained from antibodies other than IgG. Such fragments can be produced by known techniques. For example, F(ab') 2 Fragments can be produced by digestion of antibody molecules with pepsin, and Fab fragments can be produced by reducing F(ab') 2 Alternatively, Fab expression libraries can be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

[0155] Polyclonal antibodies can be obtained by immunizing suitable animals, such as rabbits, goats, etc., with viruses, collecting immune serum from the animals, and isolating the immune serum.

[0156] The present invention also includes methods for delivering heterologous nucleotide sequences to a wide range of cells, including dividing cells and non-dividing cells. The viral vectors of the present invention can be used to deliver nucleotide sequences of interest to cells in vitro, for example, to produce polypeptides in vitro or for in vitro gene therapy. The vectors can also be used in methods for delivering nucleotide sequences to individuals in need, for example, to express immunogenic or therapeutic polypeptides.

[0157] In general, the viral vectors of the present invention can be used to deliver any exogenous nucleic acid with biological effects to treat or improve any disease associated with gene expression. In addition, the present invention can be used to treat any disease that can be improved by delivering therapeutic polypeptides.Exemplary disease conditions include, but are not limited to, cystic fibrosis (cystic fibrosis transmembrane regulator) and other diseases of the lung, hemophilia A (factor VIII), hemophilia B (factor IX), thalassemia (β-globin), anemia (erythropoietin) and other blood diseases, Alzheimer's disease (GDF), multiple sclerosis (β-interferon), Parkinson's disease (glial cell line-derived neurotrophic factor), Huntington's disease (repeat-eliminating inhibitory RNA, including but not limited to RNAi, such as siRNA or shRNA, antisense RNA or microRNA), amyotrophic lateral sclerosis, epilepsy (galanin, neurotrophic factors) and other neurological diseases, cancer (endostatin, vascular , TRAIL, FAS ligands, cytokines including interferons, inhibitory RNA that inhibits VEGF including but not limited to siRNA, shRNA, antisense RNA, microRNA, multidrug resistance gene products, cancer immunogens), diabetes (insulin, PGC-α1, GLP-1, myostatin pro-peptide, glucose transporters), muscular dystrophy including Duchenne muscular dystrophy and Becker muscular dystrophy (e.g., dystrophin, mini-dystrophin, micro-dystrophin, insulin-like growth factor, etc.), glycogen storage diseases such as Fabry disease (α-galactosidase) and Pompe disease (lysosomal acid α-glucosidase), congenital emphysema (antitrypsin enzymes), Lesch-Nyhan syndrome (hypoxanthine guanine phosphoribosyltransferase), Niemann-Pick disease (sphingomyelinase), retinal degenerative diseases and other diseases of the eye and retina (PDGF, endostatin and / or angiostatin for macular degeneration), astrocytoma (endostatin, angiostatin and / or RNAi to inhibit VEGF), glioblastoma (endothelial growth factor, vascular endothelial growth factor and / or RNAi anti-vascular endothelial growth factor), liver (RNAi for hepatitis B and / or hepatitis C genes, such as siRNA or shRNA, microRNA or antisense RNA), congestive heart failure or peripheral arterial disease (phosphodiesterase), Enzyme protein inhibitor I, phospholipase, sarcoplasmic reticulum Ca2-ATPase, zinc finger protein regulating phospholipase gene, phospholipase inhibitor, etc.), arthritis (insulin-like growth factor), AIDS (soluble CD4), muscular atrophy (insulin-like growth factor I, myostatin propeptide, anti-apoptotic factors, etc.), limb ischemia (VEGF, FGF, PGC-Iα, EC-SOD, HIF), kidney deficiency (erythropoietin), arthritis (anti-inflammatory factors such as soluble receptors such as IRAP and TNFα), hepatitis (α-interferon), low-density lipoprotein receptor deficiency (LDL receptor), hyperammonemia (ornithine aminotransferase), phenylketonuria (phenylalanine hydroxylase), autoimmune diseases, etc.

[0158] The present invention can also be used after organ transplantation to increase the success rate of transplantation and / or reduce the side effects of organ transplantation or adjuvant therapy, for example, by administering immunosuppressants or inhibitory nucleic acids to block cytokine production.

[0159] Gene transfer has great potential for understanding and treating diseases. There are many genetic diseases in which defective genes are known and have been cloned. In general, the above disease states are divided into two categories: the first is a defective state, usually an enzyme defect, which is usually inherited in a recessive manner; the second is an imbalanced state, which may involve regulatory proteins or structural proteins and is usually inherited in a dominant manner. For defective state diseases, gene transfer can bring normal genes to affected tissues for replacement therapy, and use inhibitory RNA to create animal models for diseases, including siRNA or shRNA, microRNA or antisense RNA. For unbalanced disease states, gene transfer can be used to create disease states in model systems, which can then be used to treat disease states. Therefore, the viral vector according to the present invention allows the treatment of genetic diseases. As used herein, the disease state is treated by partially or completely remedying the disease or making the disease more severe defects or imbalances.

[0160] In addition, the viral vectors of the present invention have further uses in diagnostic and screening methods, wherein the gene of interest is transiently or stably expressed in a cell culture system or a transgenic animal model. The present invention can also be used to deliver nucleic acids for protein production, for example for laboratory, industrial or commercial purposes.

[0161] Alternatively, a viral vector can be administered to a cell and the altered cell administered to a subject. A heterologous nucleic acid is introduced into a cell and the cell is administered to a subject, wherein the heterologous nucleic acid encoding an immunogen is optionally expressed and an immune response to the immunogen is induced in the subject. In a specific embodiment, the cell is an antigen presenting cell, such as a dendritic cell.

[0162] An “active immune response” or “active immunity” is characterized by “the involvement of host tissues and cells following contact with an immunogen.” It involves the differentiation and proliferation of immunoregulatory cells in lymphoid tissues, leading to the synthesis of antibodies or a cell-mediated response, or both. Alternatively, an active immune response occurs after the host is exposed to an immunogen through infection or vaccination. Active immunity can be contrasted with passive immunity, which is obtained by “the transfer of preformed substances, such as antibodies, transfer factors, thymic grafts, interleukin-2, from an actively immune host to a nonimmune host.”

[0163] As used herein, a "protective" immune response or "protective" immunity indicates that the immune response confers some benefit to the subject because it prevents or reduces the incidence of a disease. Alternatively, a protective immune response or protective immunity can be used to treat a disease, particularly a cancer or tumor, e.g., to cause regression of a cancer or tumor and / or prevent metastasis and / or prevent the growth of metastatic nodules. The protective effect can be complete or partial, as long as the benefits of the treatment outweigh the disadvantages.

[0164] The viral vectors of the present invention can also be used for cancer immunotherapy by administering cancer cell antigens or immune similar molecules or any other immunogens to generate an immune response to cancer cells. For example, when treating cancer patients, an immune response against cancer cell antigens in an individual can be generated by administering a viral vector comprising a heterologous nucleotide sequence encoding a cancer cell antigen. As described herein, the viral vector can be administered to an individual in vitro or by an ex vivo method.

[0165] As used herein, the term "cancer" includes cancers that form tumors. Similarly, the term "cancer tissue" also includes tumors. "Cancer cell antigens" include tumor antigens.

[0166] The term "cancer" has its understood meaning in the art, e.g., uncontrolled tissue growth with spread or metastasis to distant parts of the body. Exemplary cancers include, but are not limited to, leukemia, lymphoma, colorectal cancer, kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, testicular cancer, ovarian cancer, uterine cancer, cervical cancer, brain cancer, bone cancer, sarcoma, melanoma, head and neck cancer, esophageal cancer, thyroid cancer, etc. In embodiments of the present invention, the present invention is implemented to treat and / or prevent neoplastic cancer.

[0167] Cancer cell antigens have been described above. The term "treating cancer" is intended to reduce the severity of cancer, prevent or at least partially eliminate cancer. For example, in certain cases, these terms indicate that the treatment of cancer is prevented or reduced, or at least partially eliminated. In another representative embodiment, these terms indicate that the growth of metastatic nodules is prevented or reduced or at least partially eliminated, for example, after surgical resection of the primary tumor. According to the term "preventing cancer", it is intended to at least partially eliminate or reduce the incidence or morbidity of cancer. In other words, the onset or progression of cancer in a subject may be slowed down, controlled, reduced in likelihood or probability or delayed.

[0168] In a specific embodiment, cells can be removed from an individual with cancer and contacted with the viral vector of the present invention. The modified cells are then administered to a subject, thereby eliciting an immune response to the cancer cell antigens. This method is particularly suitable for immunocompromised subjects who are unable to generate a sufficient immune response in vivo, i.e., unable to produce sufficient amounts of enhanced antibodies.

[0169] It is known in the art that immunomodulatory cytokines, such as alpha-interferon, beta-interferon, gamma-interferon, omega-interferon, tau-interferon, interleukin-1 alpha, interleukin-1 beta, interleukin-2, interleukin-3, interleukin-4, interleukin 5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin 12, interleukin-13, interleukin-14, interleukin-18, B cell growth factor, CD40 ligand, tumor necrosis factor-alpha, tumor necrosis factor-beta, monocyte chemoattractant protein-1, granulocyte-macrophage colony stimulating factor, and lymphotoxin, and immunomodulatory cytokines, such as CTL-inducing cytokines, can be administered to a subject together with a viral vector.

[0170] Cytokines can be injected by any method known in the art. Exogenous cytokines can be injected into the subject, or a nucleotide sequence encoding the cytokine can be delivered to the subject using a suitable vector, and the cytokine can be produced in vivo.

[0171] The recombinant viral vector according to the present invention can be used in veterinary medicine and medicine. Suitable objects include birds and mammals. The term "birds" used herein includes but is not limited to chickens, ducks, geese, quails, turkeys, pheasants, parrots. The term "mammals" used herein includes but is not limited to humans, primates, non-human primates, cattle, sheep, goats, pigs, horses, cats, dogs, rabbits, rodents, etc. Human subjects include neonates, infants, teenagers and adults. Optionally, the individual who "needs" the method of the present invention, for example, because the individual has or is believed to have a disease risk including the present invention, or will benefit from the delivery of nucleic acids including the present invention. As a further option, the subject can be a laboratory animal and / or an animal model of the disease.

[0172] In a specific embodiment, the present invention provides a pharmaceutical composition comprising a viral vector of the present invention, wherein the viral vector is in a pharmaceutically acceptable carrier, and optionally includes other agents, stabilizers, buffers, carriers, adjuvants, diluents, etc. The carrier for injection is usually a liquid. For other methods, the transport carrier can be either solid or liquid. When administered by inhalation, the carrier will be respirable, preferably in the form of solid or liquid particles.

[0173] "Pharmaceutically acceptable" refers to a material that is non-toxic or otherwise free of undesirable properties, ie, the material may be administered to a subject without producing any undesirable biological effects.

[0174] One aspect of the invention is a method for transferring nucleotide sequences into cells in vitro. Viral vectors can be introduced into cells at an appropriate multiplicity of infection according to standard transduction methods appropriate for the particular target cell. The titer of the viral vector or capsid to be administered can vary depending on the target cell type and number and the particular viral vector or capsid. In a specific embodiment, at least about 10 3 infectious units, more preferably at least about 10 5 Infectious units are introduced into cells.

[0175] The cell to be imported into the viral vector can be any type, including but not limited to neural cells, including cells of the peripheral and central nervous systems, particularly brain cells, such as neurons, oligodendrocytes, glial cells, astrocytes, pneumocytes, eye cells including retinal cells, retinal pigment epithelium and keratocytes, epithelial cells including intestinal and respiratory epithelial cells, including myoblasts, skeletal muscle cells of myotubes and myofibers, diaphragmatic cells, dendritic cells, pancreatic cells including islet cells, hepatocytes, gastrointestinal cells including smooth muscle cells and epithelial cells, heart cells including cardiomyocytes, bone marrow cells, hematopoietic stem cells, spleen cells, keratinocytes, fibroblasts, endothelial cells, prostate cells, including articular cells, germ cells including for example cartilage, meniscus, synovium and bone marrow, etc. As another option, the cell can be a stem cell, for example, a neural stem cell, a hepatic stem cell. As another option, the cell can be a cancer or tumor cell, cancer and tumor as described above. In addition, as described above, the cell can be from the source of any species.

[0176] The viral vector can be introduced into ex vivo cells to administer the modified cells to an individual. In a specific embodiment, the cells are removed from the individual, the viral vector is introduced therein, and then the cells are returned to the individual. Methods for removing cells from a subject for in vitro treatment and then reintroducing them into the subject are known in the art, see, for example, U.S. Pat. No. 5,399,346. Alternatively, the recombinant viral vector is introduced into cells from another individual, cultured cells, or cells from any other suitable source, and the cells are administered to an individual in need.

[0177] Cells suitable for in vitro gene therapy are as described above. The cell dosage administered to the subject will vary depending on the age, condition and species of the subject, the cell type, the nucleic acid expressed by the cell, the mode of administration, etc. Generally, at least 10 μg of the cell is administered per dose in a pharmaceutically acceptable carrier. 2 Up to 10 8 or about 10 3 to about 10 6 In specific embodiments, cells transduced with a viral vector are combined with a pharmaceutical carrier and administered to an individual in an effective amount.

[0178] Another aspect of the present invention is a method of administering a viral vector or capsid of the present invention to a subject. In a specific embodiment, the method includes a method of delivering a nucleic acid of interest to an animal subject, the method comprising: administering an effective amount of a viral vector of the present invention to the animal subject. The viral vector of the present invention can be administered to a human subject or an animal in need thereof by any method known in the art. Optionally, the viral vector is delivered in an effective dose in a pharmaceutically acceptable carrier.

[0179] The viral vector of the present invention can be further administered to an individual to induce an immunogenic response, for example, as a vaccine. Typically, the vaccine of the present invention comprises an effective amount of a virus in combination with a pharmaceutically acceptable carrier. Optionally, the dose is sufficient to produce a protective immune response. As long as the benefits of administering the immunogenic polypeptide outweigh any of its drawbacks, the degree of protection given does not have to be complete or permanent. The subject and the immunogen are as described above.

[0180] The dose of viral vector injected into a subject will depend on the mode of administration, the disease or condition to be treated, the individual's condition, the particular viral vector and the nucleic acid to be delivered, and can be determined in a routine manner. An exemplary dose to achieve a therapeutic effect is at least about 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 , 10 15 Tu or more virus titer, preferably about 10 7 or 10 8 ~10 12 , 10 13 or 10 14 Tu, more preferably about 10 12 Virus titer of Tu.

[0181] In specific embodiments, more than one administration may be used, for example, two, three, four or more administrations, which may be at different time intervals to achieve the desired gene expression level.

[0182] Examples of routes of administration include oral, rectal, mucosal, topical, intranasal, inhalation, oral, vaginal, intrathecal, intraocular, transdermal, intrauterine, parenteral, intravenous, subcutaneous, intradermal, intramuscular, intradermal, intrapleural, intracerebral and intraarticular, skin and mucosal surfaces, endolymphatic, etc., and direct tissue or organ injection, such as direct injection into the liver, skeletal muscle, myocardium, diaphragm or brain. Tumors can also be administered, for example, by injection into or near a tumor or lymph node. In any given case, the most appropriate route will depend on the nature and severity of the condition being treated and the nature of the specific carrier used.

[0183] Injections can be prepared in conventional forms, either as liquid solutions or suspensions, or in solid forms suitable for pre-injection liquid solutions or suspensions, or as emulsions. Alternatively, viral vectors can be administered locally rather than systemically, for example, in a specific manner, such as a sustained release formulation. In addition, viral vectors can be delivered in dry form to surgical implant matrices, such as bone graft substitutes, sutures, stents, and the like.

[0184] Pharmaceutical compositions suitable for oral administration can be presented in discrete units, such as capsules, caches, lozenges or tablets, each of which contains a predetermined amount of the composition of the present invention. As a powder or granules, as a solution or suspension of an aqueous liquid or a non-aqueous liquid, or as an oil-in-water or water-in-oil emulsion. Oral administration can be accomplished by compounding the viral vector of the present invention to a carrier that can resist degradation by digestive enzymes in the intestinal tract of an animal. Examples of such carriers include capsules or tablets known in the art. Such preparations are prepared by any suitable pharmaceutical method, the method comprising the step of combining the composition with a suitable carrier, the carrier may contain one or more excipient components as described above. In general, the pharmaceutical composition according to an embodiment of the present invention is prepared by uniformly and intimately mixing the composition with a liquid or a finely divided solid carrier or both, and then forming the resulting mixture. For example, tablets can be prepared by compressing or molding a powder or granules containing the composition, and one or more excipient components can be selected. Tablets are prepared by compressing a composition in a free-flowing form in an appropriate machine, such as a powder or granules optionally mixed with a binder, a lubricant, an inert diluent and / or a surfactant / dispersant. Tablets are formed by moistening the powdered compound with an inert liquid binder in a suitable machine.

[0185] Pharmaceutical compositions suitable for oral administration include lozenges comprising the ingredients of the invention in a flavored base, usually sucrose and acacia or tragacanth, and lozenges comprising an inert base of ingredients such as gelatin and glycerin or sucrose and acacia.

[0186] Pharmaceutical compositions suitable for parenteral administration may include sterile aqueous and non-aqueous injection solutions of the compositions of the present invention, the formulations being optionally isotonic with the blood of the intended recipient. These formulations may contain antioxidants, buffers, antibacterial agents, and solutes to make the components isotonic with the blood of the intended recipient. Aqueous and non-aqueous sterile suspensions, solutions, and emulsions may include suspending agents and thickening agents. Examples of non-aqueous solvents include propylene glycol, polyethylene glycol, vegetable oils, and injectable organic esters. Aqueous carriers include water, alcohol / water solutions, emulsions, or suspensions, including saline and buffered media. Parenteral drugs include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous carriers include liquid and nutrient supplements, electrolyte supplements, such as supplements based on Ringer's dextrose, etc. Preservatives and other additives such as antimicrobial agents, antioxidants, chelating agents, and inert gases may also be present.

[0187] The ingredients may be presented in unit-dose or multi-dose containers, for example, in sealed ampoules and vials, and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier, for example, saline or water for injection, immediately prior to use.

[0188] Extemporaneous injection solutions and suspensions can be prepared from the above-mentioned sterile powders, granules and tablets. For example, the injectable, stable, sterile composition of the present invention can be provided in a unit dose form in a sealed container. The composition can be provided in the form of a lyophilisate, which can be reconstituted with a suitable pharmaceutically acceptable carrier to form a liquid composition suitable for injection into an individual. The unit dosage form can be about 1 μg to about 10g of the composition of the present invention. When the composition is substantially insoluble in water, a physiologically acceptable sufficient amount of an emulsifier can be added to emulsify the composition in an aqueous carrier. One useful emulsifier is phosphatidylcholine.

[0189] Pharmaceutical compositions suitable for rectal administration may be presented as unit-dose suppositories. These may be prepared by mixing the ingredients with one or more conventional solid carriers and then forming the resulting mixture.

[0190] The pharmaceutical composition of the present invention suitable for topical application to the skin can take the form of an ointment, cream, lotion, paste, gel, spray, aerosol or oil. Useful carriers include, but are not limited to, vaseline, lanolin, polyethylene glycol, alcohols, transdermal enhancers, and combinations of two or more thereof. For example, in some embodiments, topical delivery can be performed by mixing the pharmaceutical composition of the present invention with a lipophilic agent that can enter the skin.

[0191] The pharmaceutical composition suitable for transdermal administration can be in the form of a discrete patch suitable for maintaining close contact with the epidermis of the subject for a long time. Compositions suitable for transdermal administration can also be delivered by iontophoresis, and are generally in the form of an optionally buffered aqueous solution of the composition of the present invention. Suitable formulations may include citrate or bis / tris buffer or ethanol / water, and may contain 0.1 to 0.2 M active ingredient.

[0192] The viral vectors disclosed herein can be administered to the lungs of an individual by any suitable method, such as administering a suspension of respirable particles composed of the viral vectors inhaled by the individual. The inhalable particulate matter can be liquid or solid. Aerosols containing liquid particles of the viral vector can be produced by any suitable method, such as using a pressure-driven aerosol nebulizer or ultrasonic nebulizer known to those skilled in the art. Aerosols containing solid particles of the viral vector can also be produced by techniques known in the medical field together with any solid particle pharmaceutical aerosol generator.

[0193] III. Directed evolution and in vivo screening of chimeric AAV capsid viral vectors

[0194] The present invention also includes a method for preparing a virus library comprising chimeric AAV capsids and then screening in vivo for chimeric AAV capsids or viruses having one or more desired properties. Non-limiting examples of desired properties include targeting characteristics, the ability to escape neutralizing antibodies, and improved intracellular trafficking.

[0195] In a representative embodiment, the present invention provides a method for identifying a viral vector having a characteristic of interest, for example, a method for identifying an AAV vector or AAV capsid having a characteristic of interest, the method comprising:

[0196] First, a collection of viral vectors, such as AAV particles, is provided, wherein each AAV vector in the collection includes: a capsid protein produced by shuffling the capsid coding sequences of two or more different AAVs, wherein the capsid amino acid sequences of the two or more different AAVs differ by at least two amino acids; and a viral vector genome, such as an AAV vector genome, wherein the viral vector genome includes the AAV capsid protein coding sequence produced by the aforementioned shuffling, a coding sequence of an AAV Rep, and at least one terminal repeat, such as the 5' and / or 3' terminal repeat of AAV, wherein the viral vector genome is encapsidated in an AAV capsid.

[0197] second, administering the collection of viral vectors to the subject;

[0198] Third, multiple viral vectors are recovered from the target tissue as viral particles or as viral vector genomes encoding AAV capsids, thereby identifying viral vectors or AAV capsids with properties of interest.

[0199] The present invention can also be used to identify a chimeric AAV capsid or virus particle that has the ability to escape neutralizing antibodies in vivo, for example, neutralizing antibodies found in human serum. For example, in vivo screening for neutralizing antibody resistance can be performed by injecting human immunoglobulin into a subject. For example, IVIG is injected into a non-human mammalian subject. IVIG naturally contains a mixture of antibodies against all common AAVs in humans. Alternatively, a subject can be injected with a specific neutralizing antibody, and then a chimeric virus library is injected into the subject, and the viral genome that enters the target tissue of interest (e.g., heart, skeletal muscle, liver, etc.) is selected, and the genome isolated from the target tissue corresponds to a capsid that can escape neutralization.

[0200] Therefore, in a representative embodiment, the present invention provides a method for identifying a chimeric AAV capsid or viral vector having the ability to escape neutralizing IgGs, the method comprising:

[0201] First, IgGs are administered to a mammalian individual;

[0202] Second, a collection of viral vectors, such as AAV particles, is provided, wherein each AAV vector in the collection includes: a capsid protein produced by shuffling the capsid coding sequences of two or more different AAVs, wherein the capsid amino acid sequences of the two or more different AAVs differ by at least two amino acids; and a viral vector genome, such as an AAV vector genome, comprising the AAV capsid protein coding sequence produced by the aforementioned shuffling, a coding sequence of an AAV Rep, and at least one terminal repeat, such as the 5' and / or 3' terminal repeat of AAV, wherein the viral vector genome is encapsidated in an AAV capsid.

[0203] third, administering the collection of viral vectors to the subject;

[0204] Fourth, multiple viral vectors are recovered from the target tissue as virions or as viral vector genomes encoding AAV capsids, thereby identifying viral vectors or AAV capsids that have the property of evading neutralizing antibodies.

[0205] By "escaping" neutralizing antibodies, it is meant that neutralization is at least partially reduced compared to an appropriate control, but the degree of "escaping" need not be complete as long as the degree of neutralization is reduced compared to a control and as long as some vector is able to reach and transduce the target tissue.

[0206] In specific embodiments, the target tissue is liver, skeletal muscle, myocardium, diaphragm muscle, kidney, pancreas, spleen, gastrointestinal tract, lung, joint tissue, tongue, ovary, testis, germ cell, cancer cell, or a combination thereof.

[0207] Any combination of sequences of two or more AAV capsids, whether naturally occurring or modified, whether now known or later discovered, can be "shuffled" to generate a collection of AAV vectors containing chimeric capsids. In a representative embodiment, the collection of AAV vectors comprises chimeric capsids generated by shuffling from two or more capsid sequences, the AAV capsids comprising: AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, avian AAV, bovine AAV, canine AAV, equine AAV, sheep AAV, goose AAV or snake AAV. As described above, the collection of AAV capsids may further comprise non-naturally occurring AAV capsids currently known or later discovered. Such modifications include substitutions, including substitutions of modified nucleic acids and / or amino acids, as well as deletions and / or insertions.

[0208] Further diversification of the chimeric capsids can be achieved by any method known in the art for introducing mutations into nucleic acid and / or amino acid sequences, such as the use of chemical mutagens, error-prone PCR, cassette mutagenesis, and the like.

[0209] Optionally, the in vivo screening method can be combined with one or more rounds of in vitro screening to further optimize the vector. For example, in vivo selection can be performed to identify chimeric AAV capsids with desired properties, and then in vitro selection can be used to identify AAV capsids with the ability to escape antibody neutralization.

[0210] The collection of AAV particles can be administered to a subject by any suitable method. In specific embodiments, the collection is administered to the subject's blood, such as intravenously or intra-articularly.

[0211] Modes of administration and subjects are as described elsewhere herein.

[0212] The present invention can be used to identify chimeric viruses or viral capsids with desired properties in vivo. Thus, in specific embodiments, the methods of the present invention include recovering AAV particles or viral genomes encoding the same AAV particles from two or more target tissues, and identifying chimeric viruses or chimeric AAV capsids that have desired properties for the two or more target tissues. For example, in specific embodiments, chimeric viruses or chimeric AAV capsids that have low efficiency targeting to skeletal muscle and / or myocardium and / or high efficiency targeting to the liver are identified.

[0213] The target cell or tissue or one of them may also be a cancer cell or tumor tissue. For example, a chimeric virus may be administered to an animal model of cancer, and a chimeric viral capsid or viral genome encoding the virus may be isolated from a cancer cell or tumor. In a representative embodiment, the animal model may be a model with an increased likelihood of forming a cancer or tumor, or may be a xenograft model in which human tumor cells are transplanted into an animal.

[0214] Exemplary methods of DNA "shuffling" or "chimerization", also known as "molecular breeding", "rapid forced evolution", etc., are known in the art (US5605793, US6165793, US6117679, Stemmer, 1994, Proc. Nati. Acad. Sci 91: 10747-10751, and Soong et al., 2000, Nature Genetics 25: 436-439). This method has also been applied to the directed evolution of viruses (US Pat. No. 6,096,548, US Pat. No. 6,596,539). In a representative embodiment, a collection of AAV capsid protein coding sequences is fragmented and recombined in vitro by homologous and / or non-homologous recombination to form a collection of "chimeric" AAV capsid proteins. Each chimeric capsid encapsulates a nucleic acid containing a corresponding capsid coding sequence, such as an AAV genome, to generate a chimeric virus. The chimeric virus collection is administered to a subject and selected in vivo according to the characteristics of interest. For example, chimeric viruses can be isolated from one or more target tissues to identify optimized capsid proteins with desired properties.

[0215] IV. Specific Embodiments

[0216] In one aspect, the present invention provides a nucleic acid encoding an AAV capsid protein, wherein the nucleic acid comprises any nucleotide sequence selected from the following groups:

[0217] (a) nucleotide sequence SEQ ID NO: 1;

[0218] (b) nucleotide sequence SEQ ID NO: 3;

[0219] (c) nucleotide sequence SEQ ID NO: 5;

[0220] (d) nucleotide sequence SEQ ID NO:7;

[0221] (e) nucleotide sequence SEQ ID NO: 9;

[0222] (f) nucleotide sequence SEQ ID NO: 11;

[0223] (g) nucleotide sequence SEQ ID NO: 13;

[0224] (h) nucleotide sequence SEQ ID NO: 15;

[0225] (i) the nucleotide sequence of SEQ ID NO: 17; or

[0226] (j) A nucleotide sequence of an AAV capsid protein encoded by any one of the nucleotide sequences of (a) to (i), which is different from the nucleotide sequence of (a) to (i) due to the degeneracy of the genetic code.

[0227] The nucleic acid is a plasmid, a bacteriophage, a viral vector, a bacterial artificial chromosome, a yeast artificial chromosome, preferably an AAV vector containing a coding sequence, and more preferably the nucleic acid further contains a coding sequence of an AAV Rep protein.

[0228] In one aspect, the present invention also provides an AAV capsid protein encoded by the above nucleic acid, wherein the amino acid sequence of the AAV capsid protein comprises any one selected from SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, or SEQ ID NO: 18. Preferably, the AAV capsid is covalently linked, bound or encapsulated with a composition selected from one or more of a DNA molecule, an RNA molecule, a polypeptide, a carbohydrate, a liposome and a small organic molecule.

[0229] In another aspect, the present invention provides a recombinant virus particle comprising the aforementioned nucleic acid and / or capsid protein. The recombinant virus particle is selected from a recombinant AAV virus particle, a recombinant adenovirus particle, a recombinant herpes virus particle, a recombinant baculovirus particle, or a recombinant hybrid virus particle.

[0230] On the other hand, the present invention provides a recombinant AAV virus particle, which comprises an AAV vector genome and the aforementioned AAV capsid protein, wherein the AAV vector genome is encapsulated in an AAV capsid. The AAV vector genome comprises a heterologous nucleic acid sequence. The heterologous nucleic acid sequence encodes one or more selected from antisense RNA, microRNA, shRNA, polypeptide and immunogen. Preferably, the polypeptide encoded by the heterologous nucleic acid sequence is a therapeutic polypeptide or a reporter gene, wherein the therapeutic polypeptide encoded by the heterologous nucleic acid is selected from one or more of the group consisting of insulin, glucagon, growth hormone, growth hormone releasing factor, erythropoietin, insulin growth factor, transforming growth factor α, hepatocyte growth factor, tyrosine hydroxylase, thrombopoietin, interleukin 1-interleukin 25, low-density lipoprotein receptor, glucocorticoid receptor, vitamin D receptor, interferon regulatory factor, factor VIII, factor IX, glucosidase, glucose-6-phosphatase, isovaleryl-CoA dehydrogenase, propionyl-CoA carboxylase, β-glucosidase, liver phosphorylase, phosphorylase kinase, glycine decarboxylase, α-galactosidase, β-galactosidase and lysosomal enzyme.

[0231] In one aspect, the present invention provides a cell comprising the aforementioned nucleic acid, AAV capsid protein, recombinant virus particle and / or recombinant AAV virus particle.

[0232] In another aspect, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and one or more selected from the aforementioned nucleic acid, AAV capsid protein, recombinant virus particle, recombinant AAV virus particle and / or the aforementioned cells.

[0233] On the other hand, the present invention also provides the use of one or more of the aforementioned nucleic acids, AAV capsid proteins, recombinant virus particles, recombinant AAV virus particles, cells and / or the aforementioned pharmaceutical compositions in the preparation of a medicament for preventing or treating a disease, wherein the disease is selected from one or more of the group consisting of cystic fibrosis and other lung diseases, hemophilia A, hemophilia B, thalassemia, anemia and other blood diseases, Alzheimer's disease, multiple sclerosis, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, cancer, diabetes, muscular dystrophy, glycogen storage disease and other metabolic defects, congenital emphysema, Lesch-Nyhan syndrome, Niemann-Pick disease, AIDS, hepatitis, hyperammonemia and spinal ataxia.

[0234] On the one hand, the present invention provides a method for preparing recombinant AAV virus particles, the method comprising providing a cell in vitro with a nucleic acid as described above, a nucleic acid coding sequence of an AAV Rep protein, an AAV vector genome carrying a heterologous nucleic acid sequence, and auxiliary factors that help produce infectious AAV, and allowing the AAV vector genome to be encapsidated in the AAV capsid encoded by the aforementioned nucleic acid, and achieving assembly of recombinant AAV virus particles. The method is an AAV vector preparation system, including a two-plasmid packaging system, a three-plasmid packaging system, a baculovirus packaging system, and an AAV packaging system with Ad or HSV as a co-virus, etc.

[0235] In one aspect, the present invention also provides a method for delivering heterologous nucleic acid to cells in vitro, the method comprising administering the aforementioned nucleic acid, viral capsid protein, recombinant viral particle, recombinant AAV viral particle and / or pharmaceutical composition to the cells, wherein the cells are mammalian cells, preferably human cells, preferably human stem cells or hepatocytes.

[0236] On the other hand, the present invention also provides a method for delivering heterologous nucleic acid to a mammal, the method comprising administering an effective dose of the aforementioned nucleic acid, viral capsid protein, recombinant viral particle, recombinant AAV viral particle, the aforementioned cell and / or the aforementioned pharmaceutical composition to the mammalian individual, wherein the mammal is a human individual or a primate individual.

[0237] After describing the present invention, the present invention will be illustrated in more detail in the following examples, which are for illustrative purposes only and are not intended to limit the present invention.

[0238] Example

[0239] The following examples describe the shuffling of AAV capsid genes by directed evolution and in vivo screening methods to generate a set of vectors with excellent or superior targeting to the liver. DNA shuffling techniques were used to shuffle AAV capsid genes and construct AAV capsid gene libraries for in vivo screening in a mouse model. AAV mutants enriched in the mouse liver were isolated and their targeting was determined by in vitro and in vivo activity testing of the AAV mutant capsids.

[0240] Example 1 Construction of chimeric AAV plasmid library

[0241] In order to obtain the chimeric AAV capsid gene Cap, the upstream primer primerA and the downstream primer primerB were first used to amplify the full-length capsid gene from different serotype AAV mothers, respectively. The selected mother AAV capsid genes included AAV1 capsid (NCBI Sequence ID: AF063497.1, the nucleic acid coding sequence of Cap 2223-4433), AAV2 capsid (NCBI Sequence ID: AF043303.1, the nucleic acid coding sequence of Cap 2203-4410), AAV3B capsid (NCBI Sequence ID: AF028705.1, the nucleic acid coding sequence of Cap 2208-4418), AAV7 capsid (NCBI Sequence ID: AF513851.1, the nucleic acid coding sequence of Cap 2222-4435), AAV8 capsid (NCBI Sequence ID: AF513852.1, the nucleic acid coding sequence of Cap 2121-4337), AAV9 capsid (NCBI Sequence ID: AF063497.1, the nucleic acid coding sequence of Cap 2223-4433), AAV10 capsid (NCBI Sequence ID: AF063497.1, the nucleic acid coding sequence of Cap 2223-4433), AAV20 capsid (NCBI Sequence ID: AF043303.1, the nucleic acid coding sequence of Cap 2203-4410), AAV3B capsid (NCBI Sequence ID: AF028705.1, the nucleic acid coding sequence of Cap 2208-4418), Sequence ID: 530579.1, Cap nucleic acid coding sequence 1-2211). The upstream primer primerA is 5'-CCCAAGCTTCGATCAACTACGCAGACAGGTACCAA-3', the downstream primer primerB is 5'-ATAAGAATGCGGCCGCAGAGACCAAAGTTCAACTGAAACGA-3', and PCR amplification is performed under the action of primeSTAR Max DNA polymerase (TaKaRa, product number R045A). The amplification conditions are: 95°C 5min for 1 cycle; 98°C 8s, 60°C 5s, 72°C 15s, 35 cycles; 72°C 5min, 1 cycle.

[0242] The amplified Cap genes were mixed with equal masses to obtain a total mass of 4ug DNA template, which was randomly fragmented and digested with 0.04U DNaseI. Under normal conditions, after digestion at 22℃ for 6-8min, the DNaseI enzyme was inactivated at 75℃ for 10min. Diffuse DNA bands were obtained by agarose gel electrophoresis, most of which were concentrated in the range of 500-1000bp, and DNA fragments in this length range were recovered.

[0243] The recovered DNA fragments were first used as primers for random primer-free amplification. In order to increase their diversity and amplification efficiency, an unconventional single annealing PCR mode was used (94°C 60s, 65°C 90s, 72°C 90s, 10 cycles; 94°C 60s, 62°C 90s, 72°C 90s, 10 cycles; 94°C 60s, 59°C 90s, 72°C 90s, 10 cycles; 94°C 60s, 56°C 90s, 72°C 90s, 10 cycles; 94°C 60s, 53°C 90s, 72°C 90s, 10 cycles; 94°C 60s, 50°C 90s, 72°C 90s, 10 cycles; 94°C 60s, 47°C 90s, 72°C 90s, 10 cycles).

[0244] The primer-free PCR product was used as a template, and the upstream primer T-primerA (5'-ACGCCTGCCGTTCGACGATTCCCAAGCTTCGATCAACTACGCAGACAGGTACCAA-3') and the downstream primer T-primerB (5'-ACGCGCGGATCTTCCAGAGATAAGAATGCGGCCGCAGAGACCAAAGTTCAACTGAAA CGA-3') were used to amplify the full length of the chimeric Cap gene under the action of HiFi DNA polymerase (TransGenBiotech, catalog number AS131-22). The amplification program was 94°C for 30 s, 62°C for 30 s, and 72°C for 2.5 min, for a total of 40 cycles. A chimeric full-length Cap DNA fragment of about 2500 bp was obtained, double-digested with HindIII and NotI, and ligated with the pSNAV2.3 vector (containing the single-stranded AAV2 genome ITR and polymerase Rep gene sequence, but lacking the Cap gene) that had been treated with the same double-digestion. The ligation product was electroporated into E. coli HST08 cells to prepare a chimeric AAV plasmid library with a library capacity of more than 1E+6 clones. Plasmids identified as positive clones by PCR were digested with PstI, HaeIII, and TaqI, and the differences in the digestion morphology of each plasmid were observed ( Figure 1 ) to determine the diversity of the plasmid library.

[0245] Example 2 Packaging and titer detection of novel AAV virus library

[0246] The chimeric plasmid library is self-packaged and replicated with the help of helper. The packaging method is a two-step method. First, the library plasmid, R2C2, and helper plasmid are transfected at a mass ratio of 1:1:2 to package into an AAV intermediate virus library. At this time, the AAV constituting the virus library is a heterozygous AAV, that is, the viral capsid protein is not necessarily expressed by the genome packaged by it. After the harvested liquid is extracted and purified by chloroform, the genome titer is detected; the second step is to infect 293T cells with an infection index MOI of 100 to ensure that the number of viral genome copies infected in each cell is less than 10. At this time, the final AAV virus library produced is a homozygous type. After the harvested liquid is extracted and purified by chloroform, the genome titer is detected (see Muller et al., 2003, Nature Biotechnology, 21:1040-1046). The quality of the library plasmid used in packaging is very low to ensure that each new AAV genome can be packaged in the shell formed by the Cap protein expressed by itself. The packaged virus particles can express capsid proteins normally, proving that they can form a complete viral capsid and have the ability to infect.

[0247] Take an appropriate amount of purified AAV sample and prepare a DNase I digestion reaction mixture according to the following table (Table 1), incubate at 37°C for 30 min and incubate at 75°C for 10 min to inactivate DNase I.

[0248] Table 1

[0249] AAV samples 5μl 10× DNase I buffer 5μl DNase I 1μl RNase-free water 39μl total 50μl

[0250] After the treated AAV purified sample is diluted to an appropriate multiple, the Q-PCR reaction system is configured according to the following table (Table 2), and the detection is performed according to the following procedures.

[0251] Table 2

[0252]

[0253] The primers used are shown in the following table (Table 3):

[0254] Table 3

[0255] Forward primer (5'-3') AAGGTGGTGGATGAGTGCTACA Reverse primer (5'-3') TGGAGCTCAGGCTGGGTTT Probe Primer CCCCAATTACTTGCTCC

[0256] The packaging output results are shown in the following table (Table 4):

[0257] Table 4

[0258] Viral vector name Genome titer (vg / ml) Novel AAV virus library 2.5E+11

[0259] Example 3 Screening and enrichment of novel AAV vectors in mice

[0260] The virus packaged by the new AAV vector was injected into 8-week-old C57BL / 6J mice through the tail vein at a dose of 1.5E+11vg / mouse for liver-targeted screening and enrichment. The mice were killed three days after the injection, and all liver tissues were collected. The total DNA was extracted after liquid nitrogen homogenization. The primer pair T-primerA / T-primerB was used for amplification again, and the DNA mixed with the amplified new AAV full-length Cap gene was constructed into the pSNAV2.3 vector using the above method. 370 positive monoclonal clones were obtained by PCR identification and mixed with equal mass to form the second plasmid library. It was packaged into a virus library and injected into 8-week-old C57BL / 6J mice again at 1.5E+11vg / mouse through the tail vein. The mice were killed three days after the injection, and all liver tissues, heart tissues and skeletal muscles were collected. 100, 50, and 50 positive clones were randomly selected from the above tissues for sequencing. The positive clones after sequencing were compared and analyzed using BioEdit, VectorNTI, ClustalX2 and TreeViewX.

[0261] We selected novel AAV vectors that appeared frequently in the liver and rarely or not in the heart and skeletal muscle. A total of 9 groups of high-frequency liver-targeting novel AAV mutants were obtained ( Figure 2 ), and analyzed the nucleotide and amino acid sequences of the above 9 novel AAV-Cap mutants (Figure 3). Since the packaging titers of the other 4 were low, they were not suitable for industrial needs. Therefore, 5 of the novel AAVs, namely L37, L57, L58, L107, and L10, were selected for subsequent infection activity test experiments.

[0262] Example 4 Infectious Activity of Novel AAV on Human Hepatocyte Cell Line in Vitro

[0263] 4.1 Testing the infection activity of novel AAV on human hepatocyte cell line in vitro using green fluorescent protein detection system

[0264] In order to preliminarily test the targeted infection activity of the new AAV on the liver, the in vitro infection activity of 6 human normal liver or liver cancer cell lines was first tested. The obtained new AAV Cap genes L57, L58, L107, and L10 were constructed into RC plasmid vectors containing type 2 AAV Rep, which carried the CAG-EGFP exogenous gene. The packaged viruses were named AAV2 / 57, AAV2 / 58, AAV2 / 107, and AAV2 / 10, and the virus titers were detected (results not shown).

[0265] The above four recombinant new AAV viruses carrying green fluorescent protein and the AAV2 / 8 recombinant virus carrying the same green fluorescent protein were used to infect various human liver cell lines at the same time. After 48 hours of infection, the infection activity was detected by flow cytometry. In order to avoid the virus vector infection efficiency being too low or oversaturated on a certain cell line, each cell line was infected with at least two infection indices (MOI). As can be seen from Figures (4A-4F), when 2-3 infection indices were used to infect human liver cell lines 7721, HepG2, Huh7, and L02, the new AAV2 / 10, AAV2 / 57, AAV2 / 58, and AAV2 / 107 showed a significant dose-dependent relationship in the infection of human liver cell lines. Next, the infection results of each cell with one of the MOIs are described, and the results of the remaining MOIs are detailed in Figure 4.

[0266] When the above four recombinant viruses were infected with human liver cell line 7402 at an infection index (MOI) of 2500, flow cytometry analysis was performed 48 hours after infection. The results ( Figure 4A ) showed that at this MOI, the infection efficiency of AAV2 / 10 was 4.6 times that of AAV2 / 8, the infection efficiency of AAV2 / 57 was 2.2 times that of AAV2 / 8, the infection efficiency of AAV2 / 58 was 3.9 times that of AAV2 / 8, and the infection efficiency of AAV2 / 107 was 1.6 times that of AAV2 / 8.

[0267] When the above four recombinant viruses were infected with human liver cell line 7721 at an infection index (MOI) of 2500, flow cytometry analysis was performed 48 hours after infection. The results ( Figure 4B ) showed that at this MOI, AAV2 / 10 had the highest infection efficiency, and AAV2 / 107 was close to it. The infection efficiency of AAV2 / 10 was 23.4 times that of AAV2 / 8, the infection efficiency of AAV2 / 107 was 21.8 times that of AAV2 / 8, the infection efficiency of AAV2 / 57 was 4.6 times that of AAV2 / 8, and the infection efficiency of AAV2 / 58 was 15.9 times that of AAV2 / 8.

[0268] When the above four recombinant viruses were infected with the human liver cell line HepG2 at an infection index (MOI) of 2500, flow cytometry analysis was performed 48 hours after infection. The results ( Figure 4C) showed that at this MOI, AAV2 / 10 had the highest infection efficiency, and AAV2 / 107 had a similar infection efficiency. The infection efficiency of AAV2 / 10 was 14.8 times that of AAV2 / 8, and the infection efficiency of AAV2 / 107 was 13.5 times that of AAV2 / 8. The infection efficiency of AAV2 / 57 was 5.5 times that of AAV2 / 8, and the infection efficiency of AAV2 / 58 was 10.9 times that of AAV2 / 8.

[0269] When the above four recombinant viruses were infected with the human liver cell line Huh7 at an infection index (MOI) of 2500, flow cytometry analysis was performed 48 hours after infection. The results ( Figure 4D ) showed that at this MOI, AAV2 / 10 had the highest infection efficiency, which was 31.8 times that of AAV2 / 8. The infection efficiency of AAV2 / 57 was 1.4 times that of AAV2 / 8, the infection efficiency of AAV2 / 58 was 6.6 times that of AAV2 / 8, and the infection efficiency of AAV2 / 107 was 19.5 times that of AAV2 / 8.

[0270] When the above four recombinant viruses were infected with the human liver cell line Huh6 at an infection index (MOI) of 10,000, flow cytometry analysis was performed 48 hours after infection. The results ( Figure 4E ) showed that at this MOI, AAV2 / 10 had the highest infection efficiency, and AAV2 / 107 had a close infection efficiency. The infection efficiency of AAV2 / 10 was 2.9 times that of AAV2 / 8, and the infection efficiency of AAV2 / 107 was 2.7 times that of AAV2 / 8. The infection efficiency of AAV2 / 57 was 1.8 times that of AAV2 / 8, and the infection efficiency of AAV2 / 58 was 2.6 times that of AAV2 / 8.

[0271] When the above four recombinant viruses were infected with the human liver cell line L02 at an infection index (MOI) of 50,000, flow cytometry was performed 48 hours after infection. The results ( Figure 4F ) showed that at this MOI, AAV2 / 10 had the highest infection efficiency, which was 42 times that of AAV2 / 8, AAV2 / 107 had a 26.8-fold increase in infection efficiency, AAV2 / 57 had a 2.5-fold increase in infection efficiency, and AAV2 / 58 had a 10.8-fold increase in infection efficiency.

[0272] From the above results, it can be seen that the infection activity of these four new recombinant AAVs on human hepatocytes or liver cancer cell lines is higher than that of the positive control AAV2 / 8.

[0273] 4.2 Testing the infection activity of novel AAV on human hepatocyte cell line in vitro using luciferase assay system

[0274] The obtained new AAV Cap genes L37, L57, L58, L107, and L10 were constructed into a RC plasmid vector containing type 2 AAV Rep, which carries the CAG-Luciferase exogenous gene. The packaged viruses were named AAV2 / 37, AAV2 / 57, AAV2 / 58, AAV2 / 107, and AAV2 / 10, and the virus titer was detected (results not shown). The above-mentioned recombinant new AAV virus was used to infect 5 normal liver or liver cancer cell lines with an infection index MOI of 500. After 48 hours, the infection activity was detected using a luciferase detection system. The infection activity was compared after deducting the NC background value from each detection value.

[0275] The infection activity of the above five recombinant novel AAV viruses on the human liver cell line Huh7 was compared. Figure 5A ) showed that the infection activity from high to low was AAV2 / 10>AAV2 / 107>AAV2 / 58>AAV2 / 37>AAV2 / 57.

[0276] The infection activity of the above five recombinant novel AAV viruses on the human hepatocyte cell line 7402 was compared. The results were ( Figure 5B ) showed that AAV2 / 10 had the highest activity, AAV2 / 107 was close to it, and AAV2 / 58 and AAV2 / 37 had similar infection activities. The infection activities were ranked from high to low as AAV2 / 10>AAV2 / 107>AAV2 / 58>AAV2 / 37>AAV2 / 57.

[0277] The infection activity of the above five recombinant novel AAV viruses on the human liver cell line 7721 was compared. The results were ( Figure 5C ) showed that AAV2 / 10 had the highest activity, while AAV2 / 58 and AAV2 / 37 had similar infection activities. The order of infection activities from high to low was AAV2 / 10>AAV2 / 107>AAV2 / 58>AAV2 / 37>AAV2 / 57.

[0278] The infection activity of the above five recombinant novel AAV viruses on the human liver cell line HepG2 was compared. The results were ( Figure 5D ) showed that AAV2 / 10 had the highest activity, and the infection activity from high to low was AAV2 / 10>AAV2 / 37>AAV2 / 107>AAV2 / 58>AAV2 / 57.

[0279] The infection activity of the above five recombinant novel AAV viruses in the human liver cell line L02 was compared. The results were ( Figure 5E ) showed that AAV2 / 10 had the highest activity, and the infection activity from high to low was AAV2 / 10>AAV2 / 107>AAV2 / 37>AAV2 / 58>AAV2 / 57.

[0280] From the above results, it can be seen that among the above-mentioned new AAVs, AAV2 / 10 has the highest activity and AAV2 / 57 has a relatively low activity.

[0281] Example 5 In vivo activity test of novel AAV

[0282] Five new AAV Cap genes L37, L57, L58, L107, and L10 were constructed into RC plasmid vectors containing type 2 AAV Rep, which carried the CAG-Luciferase exogenous gene. The packaged viruses were named AAV2 / 37, AAV2 / 57, AAV2 / 58, AAV2 / 107, and AAV2 / 10. The virus titers were detected (results not shown), and the in vivo infection activities of these new AAV viruses were compared. 6-8 week old C57BL / 6J mice were selected for tail vein injection at a dose of 1E+11vg / mouse. The mice were killed 2 weeks later, tissue DNA was extracted, and the AAV vector genome copy number in the liver, heart, and skeletal muscle was tested, and the luciferase expression in these three tissues was tested.

[0283] Vector genome copy number detection results ( Figure 6 ) showed that AAV2 / 58 had the highest vector genome copy number in the liver compared with other new AAVs, and the genome copy number in the liver was significantly increased compared with the heart and skeletal muscle of the same group; although the genome copy numbers of AAV2 / 37, AAV2 / 57, AAV2 / 107 and AAV2 / 10 vectors were lower than that of AAV2 / 58 vectors, the genome copy number in the liver was higher than that in the heart and skeletal muscle of the same group.

[0284] Luciferase expression test results ( Fig. 7A -E) showed that the luciferase expression levels of AAV2 / 37, AAV2 / 57, AAV2 / 58, AAV2 / 107, and AAV2 / 10 in the liver were higher than those in the heart and skeletal muscle of the same group.

[0285] These results indicate that all five novel AAV vectors have excellent liver targeting properties, and AAV2 / 10 has the highest luciferase expression level in the liver compared with other novel AAV vectors, followed by AAV2 / 58, then AAV2 / 37 and AAV2 / 107, which have similar luciferase expression levels in the liver, with AAV2 / 57 being relatively the lowest.

[0286] Example 6 Detection of novel AAV neutralizing antibodies in monkey serum or human serum

[0287] Because AAV is naturally infected by humans and other primates, the neutralizing antibodies produced against natural AAV will greatly reduce the half-life of AAV. Here, the neutralizing antibody level of the new AAV is tested.

[0288] 6.1 Detection and comparison of novel AAV and AAV2 / 8 neutralizing antibodies in monkey serum

[0289] In this experiment, virus infection was used, and its MOI value was fixed. The serum was diluted to detect the neutralizing antibody level of the new AAV vector and AAV2 / 8 in the serum of cynomolgus monkeys. In a series of serum dilutions, the efficiency of serum-virus mixture infection of cells was found to be 50% of the efficiency of virus-free serum infection of cells. The reciprocal of this dilution was used as the amount of neutralizing antibodies, and the neutralizing antibodies were evaluated for each viral vector (see Lochrie MA et al., 2006, Virology 353: 68-82; Mori S et al., 2006, Jpn J Infect Dis 59: 285-293, etc.). In this experiment, a total of 10 cynomolgus monkeys were tested for sera. After the serum was serially diluted, the neutralizing antibodies of the new AAV and AAV2 / 8 in each sample were determined and compared.

[0290] The specific steps are as follows: The obtained novel AAV Cap genes L37, L57, L58, L107, and L10 were constructed into RC plasmid vectors containing type 2 AAV Rep, which carried the CAG-EGFP exogenous gene. The packaged viruses were named AAV2 / 37, AAV2 / 57, AAV2 / 58, AAV2 / 107, and AAV2 / 10, and the virus titers were detected (results not shown). 7402 cells were inoculated in 24-well plates, and the serum samples of cynomolgus monkeys were serially diluted. The infection index MOI of the novel AAV viruses AAV2 / 37, AAV2 / 57, AAV2 / 58, AAV2 / 107, AAV2 / 10 and the recombinant virus AAV2 / 8 carrying the same green fluorescent protein was 2000. The diluted serum samples were mixed with the virus solution in a ratio of 1:1, and the mixture was incubated at 37°C for 1 hour, and then the mixture of serum samples and virus solution was added to the cells. The cells were harvested after 48 h, and the infection efficiency was detected by flow cytometry.

[0291] The results of neutralizing antibody detection are shown in Table 5. When the neutralizing antibody level is less than 5, it is considered to be negative for the neutralizing antibody against the virus. The 10 serum samples are numbered 1#, 2#, 3#, 4#, 5#, 6#, 7#, 8#, 9#, and 10#, among which 7# is negative for neutralizing antibodies against all viral vectors; 1# and 9# are negative for neutralizing antibodies against new AAV vectors, while neutralizing antibodies against AAV2 / 8 are positive; 2#, 3#, 4#, 5#, 6#, 8#, and 10# samples have significantly lower neutralizing antibodies against new AAV than AAV2 / 8.

[0292] Therefore, through a comprehensive comparison of the neutralizing antibodies of the new AAV and AAV2 / 8 in the serum of crab-eating macaques, the neutralizing antibodies of the new AAV in the monkey population were significantly lower than those of AAV2 / 8. As a drug delivery vector, the new AAV has lower immunogenicity.

[0293] Table 5 Neutralizing antibody test results of 10 sera from cynomolgus monkeys

[0294]

[0295] 6.2 Detection and comparison of novel AAV and AAV2 / 8 neutralizing antibodies in human serum

[0296] This experiment uses a fixed virus infection index MOI, dilutes the serum, and detects the level of neutralizing antibodies to the new AAV and the level of neutralizing antibodies to AAV2 / 8 in individual human serum. In a series of serum dilutions, find the efficiency of serum-virus mixture infection of cells is 50% of the efficiency of virus-free serum infection of cells. The reciprocal of this dilution is used as the amount of neutralizing antibodies, and the neutralizing antibodies are evaluated for each viral vector. In this experiment, a total of 10 serum samples were tested, and the serum was diluted in a series to compare the neutralizing antibodies to the new AAV and AAV2 / 8 in each sample.

[0297] The specific steps are as shown in the specific steps in 6.1, except that the serum used is normal human serum. In this experiment, 10 normal human sera were randomly selected for neutralizing antibody experiments, and the neutralizing antibodies of the new AAV and AAV2 / 8 in each sample were compared. The results of the neutralizing antibody test are shown in Table 6, among which the neutralizing antibodies of sample 3# were negative for all viruses; the neutralizing antibodies of sample 2# were negative for the neutralizing antibodies of the new AAV, but positive for the neutralizing antibodies of AAV2 / 8; the neutralizing antibodies of samples 1#, 4#, 5#, 6#, 7#, 8#, 9#, and 10# for the new AAV were significantly lower than those of AAV2 / 8. The experimental results show that in the human population, compared with the neutralizing antibodies of AAV2 / 8, the new AAV is more suitable as a drug delivery carrier and can reduce the reactogenicity.

[0298] Table 6 Neutralizing antibody test results of 10 human sera

[0299]

[0300] Based on the above results, through the comparison of neutralizing antibodies in the serum of the new AAV and AAV2 / 8, the new AAV has lower immunogenicity than the AAV2 / 8 vector and is more suitable as a gene therapy vector.

Claims

1. An adeno-associated virus capsid protein, characterized in that: The amino acid sequence of the adeno-associated virus capsid protein is shown in SEQ ID NO:

16.

2. A nucleic acid molecule encoding the adeno-associated virus capsid protein according to claim 1.

3. The nucleic acid molecule according to claim 2, wherein The nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO:

15.

4. A vector comprising the nucleic acid molecule according to claim 2 or 3, characterized in that: The vector is a plasmid, a bacteriophage, a viral vector, a bacterial artificial chromosome or a yeast artificial chromosome.

5. The vector according to claim 4, characterized in that The vector is an adeno-associated virus vector containing a coding sequence.

6. The vector according to claim 5, characterized in that The vector further comprises a coding sequence for adeno-associated virus Rep protein.

7. A composition comprising the adeno-associated virus capsid protein according to claim 1, characterized in that: The adeno-associated virus capsid protein is used for covalently linking, binding or encapsulating molecules, and the molecules are selected from one or more of DNA, RNA, polypeptide, carbohydrate, liposome and organic small molecule.

8. A recombinant virus particle, characterized in that The recombinant virus particle comprises the adeno-associated virus capsid protein of claim 1 or the nucleic acid molecule of claim 2 or 3.

9. The recombinant virus particle according to claim 8, characterized in that The recombinant virus particles are recombinant adeno-associated virus particles, recombinant adenovirus particles, recombinant herpes virus particles, recombinant baculovirus particles or recombinant hybrid virus particles.

10. A recombinant adeno-associated virus particle, characterized in that: The recombinant adeno-associated virus particle comprises an adeno-associated virus vector genome and the adeno-associated virus capsid protein according to claim 1, wherein the adeno-associated virus vector genome is encapsulated in the adeno-associated virus capsid protein.

11. The recombinant adeno-associated virus particle according to claim 10, characterized in that The adeno-associated virus vector genome contains a heterologous nucleic acid sequence.

12. The recombinant adeno-associated virus particle according to claim 11, characterized in that The heterologous nucleic acid sequence encodes one or more selected from antisense RNA, microRNA, shRNA and polypeptide.

13. The recombinant adeno-associated virus particle according to claim 12, characterized in that The polypeptide encoded by the heterologous nucleic acid sequence is a therapeutic polypeptide, an immunogen or a reporter gene.

14. The recombinant adeno-associated virus particle according to claim 13, characterized in that The therapeutic polypeptide encoded by the heterologous nucleic acid is selected from one or more of the group consisting of insulin, glucagon, growth hormone, growth hormone releasing factor, erythropoietin, insulin growth factor, transforming growth factor α, hepatocyte growth factor, tyrosine hydroxylase, thrombopoietin, interleukin 1-interleukin 25, low-density lipoprotein receptor, glucocorticoid receptor, vitamin D receptor, interferon regulatory factor, factor VIII, factor IX, glucosidase, glucose-6-phosphatase, isovaleryl-CoA dehydrogenase, propionyl-CoA carboxylase, liver phosphorylase, phosphorylase kinase, glycine decarboxylase, α-galactosidase, β-galactosidase and lysosomal enzyme.

15. A cell, characterized in that The cell comprises the adeno-associated virus capsid protein of claim 1, the nucleic acid molecule of claim 2 or 3, the vector of any one of claims 4-6 and / or the recombinant virus particle of any one of claims 8-9.

16. A cell, characterized in that The cell contains the recombinant adeno-associated virus particle according to any one of claims 10-14.

17. A cell, characterized in that The cell comprises the recombinant adeno-associated virus particle according to any one of claims 10-14, and the adeno-associated virus capsid protein according to claim 1, the nucleic acid molecule according to claim 2 or 3, and / or the vector according to any one of claims 4-6.

18. The cell according to any one of claims 15 to 17, wherein The cells are selected from one or more of Escherichia coli cells, HEK293 cell lines, HeLa cell lines, SF9 cell lines, SF21 cell lines and BHK cell lines.

19. The cell according to claim 18, characterized in that The HEK293 cell line is selected from one or more of the group consisting of HEK293T cell line, HEK293A cell line, HEK293S cell line, HEK293FT cell line, HEK293F cell line and HEK293H cell line.

20. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises a pharmaceutically acceptable carrier or excipient and one or more selected from the adeno-associated virus capsid protein of claim 1, the nucleic acid molecule of claim 2 or 3, the vector of any one of claims 4-6, the recombinant virus particle of any one of claims 8-9 and the cell of claim 15.

21. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises a pharmaceutically acceptable carrier or excipient and the recombinant adeno-associated virus particle according to any one of claims 10-14.

22. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises a pharmaceutically acceptable carrier or excipient and the recombinant adeno-associated virus particles described in any one of claims 10-14, and one or more selected from the adeno-associated virus capsid protein described in claim 1, the nucleic acid molecule described in claim 2 or 3, the vector described in any one of claims 4-6, and the cell described in claim 16 or 17.

23. Use of one or more of the adeno-associated virus capsid protein of claim 1, the nucleic acid molecule of claim 2 or 3, the vector of any one of claims 4-6, the recombinant virus particle of any one of claims 8-9, the cell of claim 15 and the pharmaceutical composition of claim 20 in the preparation of a medicament for preventing or treating a disease, wherein the disease is selected from one or more of the group consisting of hemophilia A, hemophilia B, diabetes, glycogen storage disease, Niemann-Pick disease, hepatitis and hyperammonemia.

24. Use of the recombinant adeno-associated virus particles according to any one of claims 10 to 14 in the preparation of a medicament for preventing or treating a disease, wherein the disease is selected from one or more of the group consisting of hemophilia A, hemophilia B, diabetes, glycogen storage disease, Niemann-Pick disease, hepatitis and hyperammonemia.

25. Use of a combination of one or more of the adeno-associated virus capsid protein of claim 1, the nucleic acid molecule of claim 2 or 3, the vector of any one of claims 4-6, the cell of claim 16 or 17, and the pharmaceutical composition of claim 21 or 22, and the recombinant adeno-associated virus particle of any one of claims 10-14 in the preparation of a medicament for preventing or treating a disease, wherein the disease is selected from one or more of the group consisting of hemophilia A, hemophilia B, diabetes, glycogen storage disease, Niemann-Pick disease, hepatitis and hyperammonemia.

26. A method for preparing recombinant adeno-associated virus particles, characterized in that: The method comprises providing cells in vitro with the nucleic acid molecule of claim 2 or 3, the nucleic acid coding sequence of the adeno-associated virus Rep protein, the adeno-associated virus vector genome carrying the heterologous nucleic acid sequence and auxiliary factors that help produce infectious adeno-associated virus, and allowing the adeno-associated virus vector genome to be encapsidated in the adeno-associated virus capsid protein encoded by the nucleic acid molecule of claim 2 or 3, and achieving the assembly of recombinant adeno-associated virus particles.

27. The preparation method according to claim 26, characterized in that: The method is to use an adeno-associated virus vector preparation system to prepare recombinant adeno-associated virus particles, wherein the adeno-associated virus vector preparation system includes a two-plasmid packaging system, a three-plasmid packaging system, a baculovirus packaging system, or an adeno-associated virus packaging system with adenovirus or herpes simplex virus as a co-virus.

28. A method for delivering a heterologous nucleic acid to a cell in vitro, characterized in that: The method comprises administering to cells the adeno-associated virus capsid protein of claim 1, the nucleic acid molecule of claim 2 or 3, the vector of any one of claims 4-6, the recombinant virus particle of claim 8 or 9 and / or the pharmaceutical composition of claim 20, wherein the cells are human hepatocytes.

29. A method for delivering a heterologous nucleic acid to a cell in vitro, characterized in that: The method comprises administering the recombinant adeno-associated virus particle of any one of claims 10 to 14 to a cell, wherein the cell is a human hepatocyte.

30. A method for delivering a heterologous nucleic acid to a cell in vitro, characterized in that: The method comprises administering to cells the recombinant adeno-associated virus particles described in any one of claims 10-14; and administering to cells the adeno-associated virus capsid protein described in claim 1, the nucleic acid molecule described in claim 2 or 3, the vector described in any one of claims 4-6 and / or the pharmaceutical composition described in claim 21 or 22; wherein the cells are human hepatocytes.

Citation Information

Patent Citations

  • Gene therapy

    US5399346A

  • Recombinant viral vector system

    US5478745A

  • Methods for in vitro recombination

    US5605793A

  • Adeno-associated virus materials and methods

    US5658785A

  • AAV capsid vehicles for molecular transfer

    US5863541A